CA2308151A1 - Biphenyl derivatives as pharmaceuticals - Google Patents
Biphenyl derivatives as pharmaceuticals Download PDFInfo
- Publication number
- CA2308151A1 CA2308151A1 CA002308151A CA2308151A CA2308151A1 CA 2308151 A1 CA2308151 A1 CA 2308151A1 CA 002308151 A CA002308151 A CA 002308151A CA 2308151 A CA2308151 A CA 2308151A CA 2308151 A1 CA2308151 A1 CA 2308151A1
- Authority
- CA
- Canada
- Prior art keywords
- methoxy
- compound
- formula
- biphenyl
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Abstract
Compounds of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the description, are useful as pharmaceuticals.
Description
BIPHENYL DERIVATIVES AS PHfARMACEUTICALS
The present invention relates to novel biphenyl derivatives, their preparation, their use as -pharmaceuticals and pharmaceutical compositions containing them.
More particularly the invention provides a compound of formula I
s wherein R~ and R~, independently, are hydrogen, (C~.a)alkyl, (Cm)alkox~-, (C~.4)alkylthio, halogen, trifluoromethyl, trifluoromethoxy~, cyano or (C2_s)alkanoyl, R3 is hydrogen, hydroxy, (Cm)alkyl, (Cm)alkoxy, (C~s)cycloalkylo~-, halogen, cyano, (C2.-s)alkanoyl, carbamoyl, (C»)alkylsulfonyloxy or trifluoromethylsulfonyloxy, R,, is hydrogen, hydroxy or (C»)alkoxy, and R5 is a group of formula (a), (b), (c) or (d) N_R6 N-Ra N-R6 (a) (b) (c) i~
-X- Nw (d) wherein R6 is (Cm)alkyl, X is a straight or branched alkylene chain with 1 to 4 carbon atoms, and R7 and R8, independently, are hydrogen, (Cl.a)alkyl, hydroxy(C2.a)alkyl or phenyl(G.a)alkyl, or form together with the nitrogen atom to which they are attached a pyrrolidinyl, piperidino, piperazinyl or morpholino group, or a group of formula (e) R~3 (e) Rya ."
Rya wherein Z is O, CH2 or CH2-CH2 and R9, Rio, Rn, Rl~, R3 and RI4, independently,are H, halogen, (Cm)alkyl or (Cm)alkoxy, in free base or acid addition salt form.
On account of the asymmetrical carbon atoms which rnay be present in the compounds of formula I and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.
Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
Any alkyl, alkoxy and alkylthio radicals preferably are straight chain radicals. They preferably have 1 to 3 carbon atoms, -more preferably they are methyl, methoxy and methylthio groups.
WO 99IZ3073 PC'flEP98/06880 The following significances and their combinat'~ons are preferred:
R~ and R2, independently, are hydrogen, (Ca.a)alkyl, (Cm)alkoxy, halogen or trifluoromethyl, R3 is hydrogen or in para to the phenyl substituent is hydroxy, (C»)alkoxy, (C~) cycloalkyloxy, cyano or carbamoyl, RS is a group of formula (a) or (d).
When R; is a group of formula (a), R6 is preferably methyl or propyl.
When Rs is a group of formula (d), R7 and Rs are preferably hydrogen, (Cm)alkyl or, together with the nitrogen atom to which they are attached, a group of formula (e).
When R7 and Rs, together with the nitrogen atom to which they are attached, form a group of formula (e), Z is preferably O and R9 to Rya, independently, are preferably hydrogen or methyl.
In one group of compounds of formula I, Rl, R2, R3 and Ra are as defined above and RS is a group of formula (a), (b) or (c).
In another group of compounds of formula I, R~, R2, R3 and Ra are as defined above and RS is a group of formula (d).
In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, whereby a compound of formula II
_ Y
R~
I I
The present invention relates to novel biphenyl derivatives, their preparation, their use as -pharmaceuticals and pharmaceutical compositions containing them.
More particularly the invention provides a compound of formula I
s wherein R~ and R~, independently, are hydrogen, (C~.a)alkyl, (Cm)alkox~-, (C~.4)alkylthio, halogen, trifluoromethyl, trifluoromethoxy~, cyano or (C2_s)alkanoyl, R3 is hydrogen, hydroxy, (Cm)alkyl, (Cm)alkoxy, (C~s)cycloalkylo~-, halogen, cyano, (C2.-s)alkanoyl, carbamoyl, (C»)alkylsulfonyloxy or trifluoromethylsulfonyloxy, R,, is hydrogen, hydroxy or (C»)alkoxy, and R5 is a group of formula (a), (b), (c) or (d) N_R6 N-Ra N-R6 (a) (b) (c) i~
-X- Nw (d) wherein R6 is (Cm)alkyl, X is a straight or branched alkylene chain with 1 to 4 carbon atoms, and R7 and R8, independently, are hydrogen, (Cl.a)alkyl, hydroxy(C2.a)alkyl or phenyl(G.a)alkyl, or form together with the nitrogen atom to which they are attached a pyrrolidinyl, piperidino, piperazinyl or morpholino group, or a group of formula (e) R~3 (e) Rya ."
Rya wherein Z is O, CH2 or CH2-CH2 and R9, Rio, Rn, Rl~, R3 and RI4, independently,are H, halogen, (Cm)alkyl or (Cm)alkoxy, in free base or acid addition salt form.
On account of the asymmetrical carbon atoms which rnay be present in the compounds of formula I and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.
Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
Any alkyl, alkoxy and alkylthio radicals preferably are straight chain radicals. They preferably have 1 to 3 carbon atoms, -more preferably they are methyl, methoxy and methylthio groups.
WO 99IZ3073 PC'flEP98/06880 The following significances and their combinat'~ons are preferred:
R~ and R2, independently, are hydrogen, (Ca.a)alkyl, (Cm)alkoxy, halogen or trifluoromethyl, R3 is hydrogen or in para to the phenyl substituent is hydroxy, (C»)alkoxy, (C~) cycloalkyloxy, cyano or carbamoyl, RS is a group of formula (a) or (d).
When R; is a group of formula (a), R6 is preferably methyl or propyl.
When Rs is a group of formula (d), R7 and Rs are preferably hydrogen, (Cm)alkyl or, together with the nitrogen atom to which they are attached, a group of formula (e).
When R7 and Rs, together with the nitrogen atom to which they are attached, form a group of formula (e), Z is preferably O and R9 to Rya, independently, are preferably hydrogen or methyl.
In one group of compounds of formula I, Rl, R2, R3 and Ra are as defined above and RS is a group of formula (a), (b) or (c).
In another group of compounds of formula I, R~, R2, R3 and Ra are as defined above and RS is a group of formula (d).
In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, whereby a compound of formula II
_ Y
R~
I I
wherein R3, R4, and Rs are as defined above and Y is halogen or trifluoromethyl sulfonate, is reacted with a compound of formula III
Ill R, wherein RI and R2 are as defined above, and the resulting compound is recovered in free base form or in acid addition salt form.
The reaction may~ be effected in known manner, preferably by transition metal-catalysed aryl-an-1 coupling, e.g. as described in Example 1. Hal is preferably- bromine or iodine, particularly' iodine.
Alternatively the compounds may be obtained by other well established metal-catalysed aryl-aryl coupling procedures, using for example aryl-stannyl, -zinc, -halide or Grignard precursors.
For the preparation of compounds of formula I wherein Rs is a group of formula (c), the nitrogen in the group of formula (c) may be protected e.g. by an alkoxycarbonyl group, which can be removed after the reaction with the compound of formula III
according to well=known procedures. See for example Example 11.
For the preparation of compounds of formula I wherein Rs is a group of formula (b), a compound having the formula I but wherein Rs is a 3-pyridyl group, may first be prepared as described above for the compounds of formula I, and the pyridyl group subsequently converted into the desired tetrahydropyridyl over a corresponding pyridinium salt, according to well-known procedures, for example over the pyridinium iodide as described in Example 1.
-S
For the preparation of compounds of formula I wherein RS is a group of formula (a), the corresponding compounds wherein RS is of- formula (b) may be prepared first, and subsequently hydrogenated according to well-known procedures, e.g. as described in Example S.
Compounds of formula I in optically pure form can be obtained from the corresponding racernates according to well-known procedures, e.g. as described in Examples 9 and 10.
Alternatively, optically pure starting materials can be used as described in Examples 28 and 29.
Acid addition salts may- be produced in known manner from the free base forms and vice-versa. Suitable pharmaceutically acceptable acid addition salts for use in accordance with the present invention include for example the hydrochloride, the hydrogen maleate, the hydrogen fumarate and the hydrogen malonate.
The starting materials of formula II are known or may be produced by halogenating compounds of formula IV
R, R' IV
R~
wherein R3, R4 and RS are as defined above, in accordance with known procedures.
The starting materials of formulae III and N are known or may be produced in analogous manner to known procedures, e.g. as described in the Examples.
The compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred-to collectively as "agents of the invention", exhibit pharmacological activity and are, therefore, useful as pharmaceuticals.
The agents of the invention provide long-lasting protection against maximal electroshock-induced convulsions in mice at doses of about 1 to 100 mg/kg p.o. and about 0.32 to 32 mg/kg i.p. [cf. E.A. Swinyard, J. Am.Pharrn. Assoc. Scient. Ed. 38, 201 (1949) and J.Pharmacol. Exptl. Therap. ltd, 319 (1952)}.=
The agents of the invention are therefore useful in the treatment of epilepsy and other convulsive states such as high pressure neurological syndrome.
Furthermore, the agents of the invention reduce ischaemia-induced neuronal damage and ensuing symptoms in the middle cerebral artery (MCA) occlusion model in rats at a dosage of 1-SO mg/kg i.p, i.v. and p.o. [cf. A. Tamura et al., J. Cereb. Blood Flow Metabol. 1, S3-60 (1981), A. Sauter, M. Rudin, Stroke I7, 1228-1234 (1986)].
The agents of the invention are therefore useful in the treatment of any clinical condition involving a component of cerebral anoxia, hypoxia and/or ischaernia, e.g.
ischemic damage to grey and white matter, stroke, reperfusion injury, subarachnoid haemorrhage, brain and spinal cord injury/trauma, high intracranial pressure, mufti-infarct dementia or vascular dementia, and any surgical procedure potentially associated with cerebral anoxia, hypoxia andlor ischemia (e.g. cardiac bypass, operations on extracerebral vessels).
The agents of the invention display binding to the veratridine-sensitive sodium channel with IC;os of from about 0.1 to about 100 p.M. For the binding procedure see for example J.B Brown, Journal of Neuroscience ~, 2064-2070 (1986). They block veratridine-induced glutamate release in rat hippocampal slice preparations at concentrations of about 0.1-1 mM. The experiment is performed according to a modification of M. J. Leach et al. in Epilepsia 27, 490-497 ( 1986) and Stroke 24, 1063-1067 ( 1993), using exogenous glutamate.
The agents of the. invention are accordingly indicated for use in the treatment of any pathology, disorder or clinical condition involving glutamate release in their etiology, including psychiatric disorders (such as schizophrenia, depression, anxiety, panic attacks, attention deficit and cognitive disorders, social withdrawal), hormonal conditions (excess GH [e.g. in the treatment of diabetes mellitus, angiopathy and acromegaly] or LH [prostate hypertrophy, menopausal syndrome] secretion, corticosterone secretion in stress), metabolic induced brain damage (hypoglycaemia,- =non-ketotic hyperglycinaemia [glycine encephalopathy], sulphite oxidase deficiency, hepatic encephaiopathy associated with liver failure), ernesis, spasticity, tinnitus, pain (e.g. cancer pain, arthritis) and drug (ethanol, opiates [including synthetics with opiate-like effects, e.g. pethidine, methadone etc.], cocaine, amphetamine, barbiturates and other sedatives, benzodiazepines) abuse and withdrawal.
Moreover the agents of the invention are indicated for use in the treatment of any pathology involving neuronal damage, for example neurodegenerative disorders such as Alzheimer's, Huntington's or Parkinson's diseases, virus (including HN)-induced neurodegeneration, Amyotrophic lateral sclerosis (ALS), supra-nuclear palsy, olivoponto-cerebellar atrophy {OPCA), and the actions of environmental, exogenous neurotoxins.
For the above-mentioned indications, the appropriate dosage will of course vary- depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferable from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 1 to about 300 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of epilepsy, stroke and brain or spinal trauma.
-g-The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent.
Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from 0.25 to about 2S mg of a compound according to the invention.
Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above, e.g.
epilepsy, stroke and brain or spinal trauma.
In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, e.g. epilepsy, stroke and brain or spinal trauma, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.
Exam_"ple 1~ 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3~11-1-methvl-12.5.6-tetrahvdro-A. 3-( S-bromo-2-methoxy-phenyl)-pyridine A solution of bromine (12.2 g, 3.9 ml, 0.076 mol) in glacial acetic acid (40 ml) is added dropwise over 1S minutes to a solution of 3-(2-methoxyphenyl)-pyridine (14.0 g, 0.076 mol) and anhydrous sodium acetate (6.8 g, 0.083 rnol) in glacial acetic acid (140 ml), held at 1S-20°. A precipitate is observed, which dissolves gradually upon stirring of the suspension. This suspension is left to stir for 18 hours at room temperature, after which a clear orange solution is obtained. The acetic acid is removed under reduced pressure, and the residue taken up in EtOAc (2S0 rnl). The extract is washed with water (1S0 ml), saturated agueous NaHC03 (100 ml) and brine (7S ml), dried (MgSOa), and evaporated to _g_ give the product as an orange oil. TLC (silica gel, toluene-EtOH-NHaOH
85:15:1) Rf =
0.5.
B. 3-(4-methoxy-4'-trifluorornethyl-biphenyl-3-yl)-pyridine A mixture of 3-(S-bromo-2-methoxy-phenyl)-pyridine (19.0 g, 0.072 mol), 4-trifluoromethylphenylboronic acid (14.3 g, 0.076 mol), palladiurn(II)acetate (520 mg, 0.0023 mol), tri-o-toluylphosphine (2.1 g, 0.0069 mol), 2M aqueous Na2C03 (39 ml, 0.077 mol), MeOH (80 ml) and toluene (350 ml) is heated to reflux under an argon atmosphere during 18 hours. The mixture is allowed to cool, filtered through Hyflo, diluted with water ( 100 ml), and the phases separated. The aqueous phase is extracted with toluene (150 rnl) and the combined organic phases are washed with water (100 ml) and brine (100 ml), dried (MgS04), treated with activated charcoal (1 g), filtered through Hyflo and evaporated to give a yellow oil. This oil is dissolved in EtOH (50 ml) and treated with 3N ethanolic HCl (25 ml). The hydrochloride salt precipitates upon addition of ether (20 g, 76%), m.p. 229-231°. TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.55.
C. 3-(4-methoxy-4'-triffuorornethyl-biphenyl-3-yl)-1-methyl-pyridi~niurn iodide A solution of methyl iodide (9.4 g, 66 mmol) in acetone (25 ml) is added dropwise over 15 minutes to a cool (15°) solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-pyridine (10.9 g, 33 mmol) in acetone (100 ml). The reaction mixture is then heated to reflux for 2 hours, after which a second portion of methyl iodide ( 1 ml, 2.2 g, 0.015 mmol) is added, and the mixture is allowed to reflux for a further 1.5 hours. After evaporation of the solvent, the title compound is obtained as a yellow solid, which is used directly in the following reaction. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf = 0 -0.02.
D. 3-~4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-1,2,5,6-tetrahydro-pyridine A solution of sodium hydroxide ( 1.5 g; '~6 mmol) in water ( 100 rnl) is added to a solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-pyridinium iodide in MeOH
( 150 ml). To the resulting mixture, sodium borohydride (2.5 g, 66 mrnol) are added in portions over 30 minutes, and the mixture is lefr to stir for 60 hours at room temperature.
The mixture is filtered through Hyflo and the filtrate concentrated to ca. 100 ml, upon which a yellow oil separates. This mixture is extracted with EtOAc (3 x 125 ml). The combined organic extracts are washed with brine (75 ml), dried (MgS04) and evaporated to yield the title compound as a yellowish-brown oil. TLC (silica gel, toluene-EtOH-NHaOH 85:15:1) Rf = 0.4. The hydrogen maleinate has a m.p. of 123-125°
(EtOH/Et20).
The following compounds of formula I are prepared in analogous manner to Example 1:
Examule 2: 3-i4-methoxy-biphenyl-3~r1~ 1-methyl-12.5.6-tetrahs dr~o-pyridine The hydrochloride has a m.p. of 187-194°.
Example 3: 3-(2'-chloro-4-methoxy-biphenyl-3-yl)-1-meth 1-X1.2_,5,6-tetrahydro-p The by drogen oxalate has a m.p. of 137-142°.
Example 4: 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-propyl-1.2,5.6-tetrahydro-P
The compound is obtained as a yellow oil. TT,C (silica gel, toluene-EtOH-NH40H
85:15:1)Rf=0.25.
Examy,ple 5: 3-~(4-methoxy-4'-trifluoromethyl-biphenyl-3-~ -1-meth,~piperidine Palladium on charcoal ( 10%, 700 mg) is added to a degassed solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-1,2,5,6-tetrahydro-pyridine (obtained according to Example 1 ) (5.3 g, 15.9 mmol) in glacial acetic acid (75 ml) and the mixture hydrogenated on a Parr Hydrogenator for 18 hours at room temperature and 5 atm. hydrogen pressure, during which time 70 ml of hydrogen are taken up. The catalyst is then filtered off, and fresh catalyst added (0.800 g), and the mixture further hydrogenated for 18 hours at 45°
and 5 atm, hydrogen, after which time 400 ml of hydrogen are taken up. The suspension is then filtered, the solid washed with AcOH-~d the filtrates evaporated. The residue is treated with saturated aqueous K2C03 until a basic solution ensues, which is extracted with EtOAc. The organic extracts are washed with brine (30 mI), dried (MgS04) and evaporated to give the product as a light brown oil. The hydrogen maleinate has a m.p. of 93-96° (EtOH/Et~O, dec.).
The following compounds of formula I are prepared in analogous manner to Example 5.
Example 6: 3-(4-methoxy-biphenyl-3-yl)-1-methyl-piperidine The h~fdrochloride has a m.p. of 254-262°.
Example 7: 3-!2'-chloro-4-methox~-biphen~3-yl1-1-meth~rl-piperidine The by drochloride has a m.p. of 237-247°.
Example 8: 3-(4-methoxy-4'-trifluoromethgirl-biphenyl-3-vl)-1-prowl-pipericline The hydrogen fumarate of the racemate has a m.p. of 178-180°
(EtOH/Et20, dec.).
The racernate is resolved into its enantiomers by HPLC on Chiralcel OJ, column 25 x 0.46 cm, Mobile phase: Hexane-EtOH 9:1 with 0.1% TFA. Flow rate: 1mL/min. The first enantiomer elutes with retention time 8.35 min and the second with 10.25 min.
The enantiomers are crystallised as their corresponding fumarate salts, the first has (a)DZO
+24.4 (c = 1.0, MeOH), and the second (aJD2o _ _24.3 (c = 1.0, MeOH).
Examyle 9: (-)-3-(4-methoxy-4'-trifluoromethyl-biphenyl-3=y11-1-meth ~I-piperidine A solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-piperidine (obtained according to Example 5) (7.7 g, 22 rnmol) and (-)-2,3-di-o-toluyltartaric acid hydrate (8.9 g, 22 mmol) in warm (70°) EtOH (I00 ml) is allowed to cool to room temperature and left to stand for 18 hours. - the crystals so formed are filtered off and recrystallised from 100 ml EtOH, to give crystals with a rn.p. of 155-156°; [a)D2o - _77.8 (c = 1.0 MeOH). From the crystals thus obtained the free base is formed (oil;
[a)D2o - -9,3 (c = 0.95, MeOH). These crystals are recrystallised again from EtOH (80 ml), to give crystals with a mp of 159-160°, [a)D2o - _g3.0 (c = 1.0, MeOH); free base (oil): [a)D''° -12.5 (c = 0.9, MeOH}. The hydrogen maleate has a mp of 124-126°
(EtOHIEt20); [a)D2o - -6.2 (c = 1.0, MeOH).
Example 10: t+)-3-(4-methoxy-4'-triffuoromethvl-biphenyl-3-vll-1-meth l~l-piperidine The mother liquors from Example 9 are reserved, and free base is prepared from each by treating with sat. aqueous K2C03 and extraction with EtOAc. The free base obtained from the first mother liquors (2,4 g, 6.88 mmol) is treated with (+)-2,3-di-o-toluyltartaric acid hydrate (2.6 g, 6.88 mmol) in boiling EtOH (40 ml), which upon cooling yields crystals which are recrystallised from EtOH (25 ml) to give colourless crystals with a mp of 164-165°, [a)D2° _ + 81.1 (c = 1.1, MeOH) from which the free base has a [a)D2° of + 11.3 (c = 1.0, MeOH). The free base from the combined second and third mother liquors (3.6 g, 10.3 mmol) are combined with (+)-2,3-di-o-toluyitartaric acid hydrate (3.9 g, 10.3 mmol) in boiling EtOH (50 ml). After complete crystallisation , the crystals are recrystallised from EtOH (45 ml) to give a crop of crystals having a [a]n2° of +
85.2 (c = 1.0, MeOH) from which the free base has a [a)D2o of + 9.8 (c = 1.4, MeOH), and are further recrystallised from EtOH (30 ml) to give crystals with a m.p. of 164-165°;
[a)DZO = +87,3 (c = i.0, MeOH) from which the free base has a [a)D2o of + 11.3 (c = 1.0, MeOH). The hydrogen maleate has a m.p. of 125-127° (EtOH/Et20); [a)DZO
= + 5.4 (c =
1.1, MeOH) -Example 11: 3-(4-methoxy-4'-trifluorom~yl-biphenyl-3-vl~l-methyl-pyrrolidine A. 1-ethoxycarbonyl-3-(2-methoxyphenyl)-pyrrolidine A solution of ethylchloroformate (0.61 ml, 673 mg, 6.21 mmol) in CH2Cl2 (3 rnl) is added dropwise over 10 minutes to a cold (~5°, ice-bath) solution of N-ethyl-N,N-diisopropylamine (1.3 ml, 911 mg, 7.01 mmoi) and 3-(2-methoxyphenyi)-pyrrolidine (1.00 g, 5.65 mmol) in CH~C12 ( 15 rnl). The yellow reaction mixture is left to stir for 3.5 hours at room temperature, after which it is washed with 1N HCl ( 15 ml), saturated aqueous NaHC03 ( 15 ml) and brine ( 10 rnl), dried (MgS04) and the solvent evaporated to .give the product as a yellow oil. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf =
0.6.
B. 1-ethoxycarbonyl-3-(5-bromo-2-methoxyphenyl)-pyrrolidine A solution of bromine (835 mg, 5.22 matg) in glacial acetic acid (3 ml) is added dropwise to a solution of 1-ethoxycarbonyl-3-(2-methoxyphenyl)-pyrrolidine (1.300 g, 5.22 mmol) and sodium acetate (470 mg, 5.70 mmol) in glacial acetic acid (15 ml), and the mixture is left to stir for 18 hours at room temperature. The mixture is filtered through Hyflo and the solvent evaporated. The residue is taken up in ethyl acetate (30 ml) and the solution washed with water (20 ml), saturated aqueous Na2C03 (20 ml) and brine (15 rnl). The aqueous phases are extracted with EtOAc (25 ml) and the combined organic extracts dried (MgSOa) and evaporated to give the product as a yellow-brown oil [TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.6] which is used directly in the following reaction.
C. 1-ethoxycarbonyl-3-(4-methoxy-4'-tritluoromethlyl-biphenyl-3-yl)-pyrroliaine Obtained from 1-ethoxycarbonyl-3-(5-bromo-2-methoxyphenyl)-pyrrolidine and 4-trifluoromethylphenyl-boronic acid by palladium-catalysed coupling in analogous manner to Example 1B. TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.78. The crude product is used directly in the following reaction.
D. 3-_(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-pyrrolidine The crude product obtained under C (2.00 g) is dissolved in THF (15 ml) and added dropwise over 15 minutes to a cold (0-5°) suspension of lithium aluminium hydride (350 mg, 9.2 mmol) in THF (25 ml). The reaction mixture is allowed to stir at room temperature for 1 hour and heated to reflux for 18 hours, after which it is allowed to cool to room temperature, and treated by t~ careful sequential addition of saturated aqueous NazSOa (2m1), 2N NaOH (2 ml), and Et20 (SO ml). The mixture is stirred vigorously 1 hour at room temperature, and the precipitate filtered off. The precipitate is further washed with Et20-THF (1:1 30 ml), and the combined filtrates dried (MgS04) and evaporated to give a reddish oil. This crude product is dissolved in Et20 (SO ml) and extracted with 2N HCl (2x 1S ml). The combined acid phases are further extracted with Et20 (20 ml), cooled (ice-bath), made alkaline with sat. aq.
K2C03 and extracted with Et20 (SO ml). The ether extracts are washed with brine (30 ml), dried (MgSOa) and evaporated to give the product as a reddish oil. TLC (silica gel, toluene-EtOH-NHaOH 8S:IS:1) Rf = 0.1. The hydrogen fumarate has a m.p. of I76-180°
(dec.).
Example 12 2 (4' trifluorometh~phenyl-3-vl)ethvlamine A mixture of 3-(bromophenyl)-ethylamine (1.400 g, 7.0 mmol) , 4-trifluoromethyl-phenylboronic acid (1.33 g, 7.0 mmol), tris-(ortho-toluyl)phosphine (212 mg, 0.70 mmol), palladium (II) acetate (160 mg, 0.7 rnmol), aqueous sodium carbonate solution (2M, 3.S ml), MeOH (2 ml) and toluene (2S ml) is heated to reflux under argon for 18 hours. The mixture is then allowed to cool to room temperature, and the phases are separated. The aqueous phase is extracted with toluene (2S ml). The combined organic phases are washed with water (2S rnl) and brine (30 ml), dried (MgS04) and evaporated. The residue is purified by chromatography (silica gel, toluene-ethanol-NH40H 85:15:1) to yield the product as a light yellow oil. TLC (silica gel, toluene-ethanol-NHaOH 8S:1S:1)Rf = 0.30.
Example I3 N N dimethvl 12 (4'-trifluoromethvl-biphenyl-3-vllethvllamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 150-153°
(EtOH/Et~O).
The compound can also be obtained by dimethylation of the compound of Example according to known procedures, e.g. by Eschwe~ler-Clarke methylation.
Example 14: 2-(6-methoxy-4'-tritluoromethLl-biphen~~yl)ethylamine Obtained analogously to Example 12 as a yellow oil. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf = 0.30.
Example 1S: N.N-dimethyl-f2-(6-methoxy-4'-trifluoromethyl-biphenyl-3-yl)ethyllarnine Obtained analogously to Example 12. The hydrochloride has a m.p, of 210-212°
(EtOH/Et20)..
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 14.
Example 16: 2-(4-methoxy-4'-tiifluoromethyl-biphenyl-3-yl)~thvlamine Obtained analogously to Example I2. The hydrogen rnaleate has a m.p. of 157-160°
(EtOH).
Example 17: N.N-dimeth~rl-2-f(4-methoxy-4'-trifluoromethyl-biphenyl-3-vl)ethyl-]amine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 136-137°
(EtOH).
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 16. -Example 18: N-propyl-2-[4-methoxy-4'-trifluorometh~phenyl-3-yl?Leth~lamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 178-180°
(EtOH/Et~O). -Example 19: 1-[2-f4-methoxv-4'-trifluommeth~phenyl-3-yllethyl]py~olidine Obtained analogously to example 12. The hydrogen maleate has a m.p. of 131-133°
(EtOHlEt20).
The compound can also be obtained as follows:
A. 1-[2-(4-methoxy-4'-tritluoromethyl-biphenyl-3-yl)-ethyl-pyrroIidine-2,5-dione A solution of 2-(4-methoxy-4'-trifluoromethylbiphenyl-3-yi)-ethylarnine (1.4 g, 4.74 mmol) and succinic anhydride (475 mg, 4.74 mmol) in THF (60 ml) is heated to reflux for I8 hours. The solution is then evaporated to dryness, and the residue heated to 190° to give an oil that crystallises on standing, and is recrystallised (Et20) to yield the product, m.p. 116-120°.
B. 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylJpyrrolidine A solution of 1-(2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyl-pyrrolidine-2,5-dione (1.3 g, 3.45 mmol) in THF (10 ml) is added dropwise over 10 minutes to a suspension of lithium aluminium hydride (262 mg, 6.9 mmol) in THF (15 ml) held at 0-10°. When the addition is complete, the mixture is allowed to warm up to room temperature, and stirred for 1 hour, after which the mixture is heated to reflux for i8 hours. After cooling, the reaction mixture is treated sequentially with saturated aqueous Na2SOa (2 ml) and aqueous NaOH (2N, 1 ml). After addition of Et20 (25 rnl) the resulting mixture is stirred for 1 hour, and then filtered. The precipitate is washed with Et20, and the washings combined with the filtrate. The Et20 solution is dried (MgS04) and evaporated to give a yellow oil which is purified by crystallisation as its hydrogen maleate.
Example 20: (1S''.2S~',6R"'.7R~)- 4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyll-10-oxa-4-aza-tricyclo [S .2.1.0 (,2 L6~] decane Obtained analogously to Example 12. The-hydrogen male ate has a rn.p. of 163-164°
(EtOH/Et20). The compound can also be obtained as follows:
A. (2S ;2R*,6S*',7R~')-4-[2-(4-methoxy- 4'-trifluoromethyl-biphenyl-3-yl)-ethyl]-10-oxa-4-aza-tricyclo[5.2.1.0(2,6)]decane-3,5-dione A solution of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)ethylamine (1.4 g, 4.74 mmol) and (IS*,2R *,6S*,7R *)-4,10-dioxa-tricyclo[5.2.1.0(2,6)]decane-3,5-dione (850 mg, 5.1 mmol) in THF (60m1) is heated to reflux for 18 hours, in similar fashion to example 8A, to give the product, mp. 166-168°.
B.(1S*',2S ;6R ;7R*')-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylJ-10-oxa-4-aza-tricyclo[5.2.1.0(2,6)]decane The product from Example 20A is reduced with lithium aiuminium hydride in THF
to give the product as a brown oil which is crystallised as its hydrogen maleate salt.
Example 21: f 1S'~.2S*.6R*.7R*1- 4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-eth~l~,-10-oxa-4-aza-2.6-dimeth I-~yclo[5.2.1.0(2.6)]decane Obtained analogously to Example 12. The hydrochloride has a m.p. of 229-231°. The compound can also be obtained as follows:
A. (IS~',2R ;6S*,7R*')-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyl]-10-oxa-4-aza-2,6-dimethyl-tricyclo [5 .2.1.0(2,6 ) J decane-3,5-dione Obtained in a similar fashion to example 20A from of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylamine and (1 R *,2S*,6R *,7S*)-2,6-dimethyl-4,10-dioxa-tricyclo [5.2:1.0(2,6)]decane-3,S-dione. Mp. 115-117°
(Et20/hexane) B. (ZS*,2Sx,6R*',7R*)-4-[2~4-methoxy-4'-trifluorornethyl-biphenyl-3-yl)-ethyl]- I 0-oxa-4-aza-2,6-dimethyl-tricyclo [S .2.1.0 ( 2,6 ) ] decane Obtained in similar fashion to Example 20B by reduction of (I R *,2S *,6R *,7S
*)-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl~~:ethyl]-10-oxa-4-aza-2,6-dimethyl-tricyclo[5.2.1.0(2,6)]decane-3,5-dione.
Example 22 2-~,4'-isopropyl-4-methoxy-biphenyl-3-v11-ethvlamine Obtained analogously to Example 12. TLC (silica gel, EtOAc-MeOH-NH40H 0:20:2) Rf = 0.22.
Examvle 23~ N11T dimethYl_-2-(4'-isovropyl-4-methoxy-biphenyl-3-vl)-ethvlamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 123-124°
(EtOH/Et~O).
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 22.
Examule 24- 2-(2'-chloro-4-methoxy-biphen~yll-ethvlamine Obtained analogously to Example 12. The hydrochloride has a m.p. of 191-205°.
ExamQ,le 25' N N-dimeth~l-2-!2'-chloro-4-methoxY biphenyl-3-vl)-ethvlamine Obtained analogously to Example 12. The hydrochloride has a m.p. of 151-159°.
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 24.
Exam,~le 26~ (2'-ehloro-4-methoxy-biphenyl-3-yl-methyl)-N,N-dimethvlamine Obtained analogously to Example 12. The hydrogen oxalate has a m.p. of 145-159°.
Example 27~ N.N dimethyl_-2-(2'-chloro-4-methoxy-biphen~-3-yl)-1-methyl-ethvlamine Obtained analogously to Example 12. The hydrochloride has a rn.p. of 141-145°.
Example 28~ (+) f2 f4 Methoxy-4'-trifluorometh~phenyl-3-ill-1-methyl-ethvll-N,N-dimethy_I-amine A. Z-1-Methoxy-2-(2-nitropropenyl)-benzene A solution of 10 g of 2-methoxybenzaldehyde, 6.07 g of nitroethane, 0.8 ml of butylamine and 30 ml of ethanol is refluxed for 3 days, the ethanol evaporated and the remaining mixture dissolved in ethyl acetate. After extraction with water and brine the solvent is evaporated and the residue bulb to bulb distilled. The fraction distilling at 120 - 170° I 0.01 mbar is purified on silicagel by elution with methylenechloride I
cyclohexane 1:1 giving the title compound in form of yellow plates, m.p. 39 -42°.
B. rac-2-(2-Methoxy-phenyl)-1-methyl-ethylamine A solution of 45.01 g (233 mmol) of Z-1-methoxy-2-(2-nitropropenyl)-benzene in ml of ether is slowly dropped into a flask equipped with a mechanical stirrer, thermometer and reflux condenser containing 40.84 g of LiAlH4 in 600 ml of diethyl ether. The exothermic reaction is cooled with ice and the temperature kept between 5 -10°. After stirring overnight at room temperature 330 ml of 2M Na2C03 are added, the resulting suspension filtered and the ether phase extracted with 2M HCI.
The acidic aqueous phase is made alkaline with 1.2 equivalents of conc. ammonia and extracted with diethyl ether. The ether phase is washed with brine, dried over Na2S04 and concentrated to afford the title compound as a yellow oil.'H-NMR (360 MHz, CDCl3):7.2t,1H;7.1d,1H;7.0-6.8m,2H;3.9s,3H;3.2m,1H;2.8m,1H;2.6 m, 1H; 1.1 d, 3H.
Further purification is achieved by transformation of the compound into the naphthalene-1,5-disulfonate salt.
C.1 (-)-2-(2-Methoxy-phenyl)-1-methyl-ethylamine To 19.16 g of rac-2-{2-methoxy-phenyl)-1-methyl-ethylamine dissolved in 300 ml of methanol a solution of 17.49 g of D-(-)-tarta~c acid in 334 ml of methanol is added and the mixture kept at 4° for 3 hours. The solid is filtered, the mother liquor put aside and the filter cake washed with ice-cold methanol and recristallised twice from methanol until the optical rotation remained constant. One obtains 11.11 g of (-)-2-(2-methoxy-phenyl)-1-methyl-ethylamine D-tartaric acid salt as fine white plates, m.p.
144 - 149°. The free base show a specific rotation of [a]ss9= -35.4° (c=1, MeOH).
Analytical chiral capillary electrophoresis of the free base reveals an optical purity of >98%.
C.2 (+)-2-(2-Methoxy-phenyl)-1-methyl-ethylamine The first mother liquor obtained in the preparation of the (-)-enantiomer of C.1 is concentrated and the residue liberated from the tartrate by treatment with conc.
ammonia and ethyl acetate. After evaporation of the organic layer, 11.14 g of a yellow oil are obtained and combined with 10.12 g of L-(+)-tartaric acid in a total volume of 140 ml of methanol. After 3 h at 4°, the formed solid is collected, washed with ice-cold methanol and recristallised from methanol until the specific rotation remains constant.
One obtains 11.92 g of (+)-2-(2-methoxy-phenyl)-1-methyl-ethylamine-L-tartaric acid salt as white plates. The free base show a specific rotation of [a]ss9 =
+37.7° (c=1, MeOH). Analytical chiral capillary electrophoresis reveals an optical purity of >98%.
D. (-)-[2-(2-Methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine 11.8 g of the tartaric acid salt of (+)-2-(2-methoxy-phenyl)-1-methyl-ethylamine are liberated with conc. ammonia in ethyl acetate and the obtained oil is dissolved in 56 ml of methanol. To this solution 22.3 ml of 36.5% aqueous formaldehyde solution are added, the mixture cooled to 3° and treated in small portions with 10.66 g of NaCNBH3. After 22 h of stirring at room temperature, the solvent is evaporated and the residue distributed between ethyl acetate and water. The organic phase is washed with water and brine, dried over Na2SC~, concentrated and the residue purified on silicagel by elution with toluene l ethyl acetate I methanol l conc. ammonia 60:30:10:1 yielding 5.02 g of the title compound as a yellow oil with [a]ss9 = -19.9° (c = 1, MeOH).'H-NMR (360 MHz, CDC13): 7.2 dxt, 1H; 7.1 dxd, 1H; 7.0 - 6.8 m, 2H;
3.85s,3H;3.1-3.Om,1H;2.95-2.85m,k~i;2.4brs,7H;0.95d,3H.
E. (+)-[2-(S-bromo-2-methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine To a mixture of 4.47 g of (-)-[2-(2-methoxy-phenyl)-1-methyl-ethyl]-dimethyl-amine, 2.09 g of sodium acetate and 40 ml of glacial acetic acid in a mechanically stirred flask, 1.19 mI of bromine in 8.5 ml of glacial acetic acid are added dropwise at 20 -30°. The reaction mixture is stirred for 16 h, neutralised with conc.
ammonia and extracted with ethyl acetate. Drying of the organic layer with brine and NazS04, evaporation of the solvent and purification of the obtained residue on silicagel with toluene I ethyl acetate I methanol I conc. ammonia 60:30:10:1 give 4.32 g of the title compound as a brown oil, [a)589 = +1.5° (c = 1.01, MeOH). 1H-NMR (360 MHz, CDC13):7.2-7.Om,2H;6.60d, 1H;3.70s,3H;2.95-2.75m,2H;2.3-2.2m+s, 7H; 0.85 d, 3H.
F. (+)-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-N,N-dimethyl-amine A 500 rnl-flask is charged with 140 ml of toluene and 28 ml of 2M Na2C03 and gased with argon for 1 h. Then 3.94 g of (+)-[2-(5-bromo-2-methoxy-phenyl)-1-methyl-ethyl]-dimethyl-amine, 4.95 g of 4-trifluoromethyl-phenylboronic acid and 374 mg of tetrakis(triphenylphosphine)palladium are added and the mixture is refluxed for 12 h.
The aqueous layer is extracted with ethyl acetate and the combined organic phases are washed with brine, dried over NazS04 and concentrated to afford a brown oil.
Formation of the naphthalene-1,5-disulfonate salt of this oil and liberation of the free base allow to cristallise the product as hydrochloride salt from HCl in diethyl ether.
Recristallisation ffom ethanol I ether afford the hydrochloride of the title compound as fine white plates, rn.p. 155 - 163°.
The free base solidifies with a m.p. of 36~- 37° and shows a specific rotation of [a]s89 =
+13.0° (c = 0.995, MeOH). Analytical chiral HPLC (Chiracel OJ) reveals an optical purity of >99%.'H-NMR (360 MHz, CDC13): 7.70 s, 4H; 7.45 dxd, 1H; 7.40 d, 1H;
Ill R, wherein RI and R2 are as defined above, and the resulting compound is recovered in free base form or in acid addition salt form.
The reaction may~ be effected in known manner, preferably by transition metal-catalysed aryl-an-1 coupling, e.g. as described in Example 1. Hal is preferably- bromine or iodine, particularly' iodine.
Alternatively the compounds may be obtained by other well established metal-catalysed aryl-aryl coupling procedures, using for example aryl-stannyl, -zinc, -halide or Grignard precursors.
For the preparation of compounds of formula I wherein Rs is a group of formula (c), the nitrogen in the group of formula (c) may be protected e.g. by an alkoxycarbonyl group, which can be removed after the reaction with the compound of formula III
according to well=known procedures. See for example Example 11.
For the preparation of compounds of formula I wherein Rs is a group of formula (b), a compound having the formula I but wherein Rs is a 3-pyridyl group, may first be prepared as described above for the compounds of formula I, and the pyridyl group subsequently converted into the desired tetrahydropyridyl over a corresponding pyridinium salt, according to well-known procedures, for example over the pyridinium iodide as described in Example 1.
-S
For the preparation of compounds of formula I wherein RS is a group of formula (a), the corresponding compounds wherein RS is of- formula (b) may be prepared first, and subsequently hydrogenated according to well-known procedures, e.g. as described in Example S.
Compounds of formula I in optically pure form can be obtained from the corresponding racernates according to well-known procedures, e.g. as described in Examples 9 and 10.
Alternatively, optically pure starting materials can be used as described in Examples 28 and 29.
Acid addition salts may- be produced in known manner from the free base forms and vice-versa. Suitable pharmaceutically acceptable acid addition salts for use in accordance with the present invention include for example the hydrochloride, the hydrogen maleate, the hydrogen fumarate and the hydrogen malonate.
The starting materials of formula II are known or may be produced by halogenating compounds of formula IV
R, R' IV
R~
wherein R3, R4 and RS are as defined above, in accordance with known procedures.
The starting materials of formulae III and N are known or may be produced in analogous manner to known procedures, e.g. as described in the Examples.
The compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred-to collectively as "agents of the invention", exhibit pharmacological activity and are, therefore, useful as pharmaceuticals.
The agents of the invention provide long-lasting protection against maximal electroshock-induced convulsions in mice at doses of about 1 to 100 mg/kg p.o. and about 0.32 to 32 mg/kg i.p. [cf. E.A. Swinyard, J. Am.Pharrn. Assoc. Scient. Ed. 38, 201 (1949) and J.Pharmacol. Exptl. Therap. ltd, 319 (1952)}.=
The agents of the invention are therefore useful in the treatment of epilepsy and other convulsive states such as high pressure neurological syndrome.
Furthermore, the agents of the invention reduce ischaemia-induced neuronal damage and ensuing symptoms in the middle cerebral artery (MCA) occlusion model in rats at a dosage of 1-SO mg/kg i.p, i.v. and p.o. [cf. A. Tamura et al., J. Cereb. Blood Flow Metabol. 1, S3-60 (1981), A. Sauter, M. Rudin, Stroke I7, 1228-1234 (1986)].
The agents of the invention are therefore useful in the treatment of any clinical condition involving a component of cerebral anoxia, hypoxia and/or ischaernia, e.g.
ischemic damage to grey and white matter, stroke, reperfusion injury, subarachnoid haemorrhage, brain and spinal cord injury/trauma, high intracranial pressure, mufti-infarct dementia or vascular dementia, and any surgical procedure potentially associated with cerebral anoxia, hypoxia andlor ischemia (e.g. cardiac bypass, operations on extracerebral vessels).
The agents of the invention display binding to the veratridine-sensitive sodium channel with IC;os of from about 0.1 to about 100 p.M. For the binding procedure see for example J.B Brown, Journal of Neuroscience ~, 2064-2070 (1986). They block veratridine-induced glutamate release in rat hippocampal slice preparations at concentrations of about 0.1-1 mM. The experiment is performed according to a modification of M. J. Leach et al. in Epilepsia 27, 490-497 ( 1986) and Stroke 24, 1063-1067 ( 1993), using exogenous glutamate.
The agents of the. invention are accordingly indicated for use in the treatment of any pathology, disorder or clinical condition involving glutamate release in their etiology, including psychiatric disorders (such as schizophrenia, depression, anxiety, panic attacks, attention deficit and cognitive disorders, social withdrawal), hormonal conditions (excess GH [e.g. in the treatment of diabetes mellitus, angiopathy and acromegaly] or LH [prostate hypertrophy, menopausal syndrome] secretion, corticosterone secretion in stress), metabolic induced brain damage (hypoglycaemia,- =non-ketotic hyperglycinaemia [glycine encephalopathy], sulphite oxidase deficiency, hepatic encephaiopathy associated with liver failure), ernesis, spasticity, tinnitus, pain (e.g. cancer pain, arthritis) and drug (ethanol, opiates [including synthetics with opiate-like effects, e.g. pethidine, methadone etc.], cocaine, amphetamine, barbiturates and other sedatives, benzodiazepines) abuse and withdrawal.
Moreover the agents of the invention are indicated for use in the treatment of any pathology involving neuronal damage, for example neurodegenerative disorders such as Alzheimer's, Huntington's or Parkinson's diseases, virus (including HN)-induced neurodegeneration, Amyotrophic lateral sclerosis (ALS), supra-nuclear palsy, olivoponto-cerebellar atrophy {OPCA), and the actions of environmental, exogenous neurotoxins.
For the above-mentioned indications, the appropriate dosage will of course vary- depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferable from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 1 to about 300 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of epilepsy, stroke and brain or spinal trauma.
-g-The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent.
Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from 0.25 to about 2S mg of a compound according to the invention.
Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above, e.g.
epilepsy, stroke and brain or spinal trauma.
In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, e.g. epilepsy, stroke and brain or spinal trauma, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.
Exam_"ple 1~ 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3~11-1-methvl-12.5.6-tetrahvdro-A. 3-( S-bromo-2-methoxy-phenyl)-pyridine A solution of bromine (12.2 g, 3.9 ml, 0.076 mol) in glacial acetic acid (40 ml) is added dropwise over 1S minutes to a solution of 3-(2-methoxyphenyl)-pyridine (14.0 g, 0.076 mol) and anhydrous sodium acetate (6.8 g, 0.083 rnol) in glacial acetic acid (140 ml), held at 1S-20°. A precipitate is observed, which dissolves gradually upon stirring of the suspension. This suspension is left to stir for 18 hours at room temperature, after which a clear orange solution is obtained. The acetic acid is removed under reduced pressure, and the residue taken up in EtOAc (2S0 rnl). The extract is washed with water (1S0 ml), saturated agueous NaHC03 (100 ml) and brine (7S ml), dried (MgSOa), and evaporated to _g_ give the product as an orange oil. TLC (silica gel, toluene-EtOH-NHaOH
85:15:1) Rf =
0.5.
B. 3-(4-methoxy-4'-trifluorornethyl-biphenyl-3-yl)-pyridine A mixture of 3-(S-bromo-2-methoxy-phenyl)-pyridine (19.0 g, 0.072 mol), 4-trifluoromethylphenylboronic acid (14.3 g, 0.076 mol), palladiurn(II)acetate (520 mg, 0.0023 mol), tri-o-toluylphosphine (2.1 g, 0.0069 mol), 2M aqueous Na2C03 (39 ml, 0.077 mol), MeOH (80 ml) and toluene (350 ml) is heated to reflux under an argon atmosphere during 18 hours. The mixture is allowed to cool, filtered through Hyflo, diluted with water ( 100 ml), and the phases separated. The aqueous phase is extracted with toluene (150 rnl) and the combined organic phases are washed with water (100 ml) and brine (100 ml), dried (MgS04), treated with activated charcoal (1 g), filtered through Hyflo and evaporated to give a yellow oil. This oil is dissolved in EtOH (50 ml) and treated with 3N ethanolic HCl (25 ml). The hydrochloride salt precipitates upon addition of ether (20 g, 76%), m.p. 229-231°. TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.55.
C. 3-(4-methoxy-4'-triffuorornethyl-biphenyl-3-yl)-1-methyl-pyridi~niurn iodide A solution of methyl iodide (9.4 g, 66 mmol) in acetone (25 ml) is added dropwise over 15 minutes to a cool (15°) solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-pyridine (10.9 g, 33 mmol) in acetone (100 ml). The reaction mixture is then heated to reflux for 2 hours, after which a second portion of methyl iodide ( 1 ml, 2.2 g, 0.015 mmol) is added, and the mixture is allowed to reflux for a further 1.5 hours. After evaporation of the solvent, the title compound is obtained as a yellow solid, which is used directly in the following reaction. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf = 0 -0.02.
D. 3-~4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-1,2,5,6-tetrahydro-pyridine A solution of sodium hydroxide ( 1.5 g; '~6 mmol) in water ( 100 rnl) is added to a solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-pyridinium iodide in MeOH
( 150 ml). To the resulting mixture, sodium borohydride (2.5 g, 66 mrnol) are added in portions over 30 minutes, and the mixture is lefr to stir for 60 hours at room temperature.
The mixture is filtered through Hyflo and the filtrate concentrated to ca. 100 ml, upon which a yellow oil separates. This mixture is extracted with EtOAc (3 x 125 ml). The combined organic extracts are washed with brine (75 ml), dried (MgS04) and evaporated to yield the title compound as a yellowish-brown oil. TLC (silica gel, toluene-EtOH-NHaOH 85:15:1) Rf = 0.4. The hydrogen maleinate has a m.p. of 123-125°
(EtOH/Et20).
The following compounds of formula I are prepared in analogous manner to Example 1:
Examule 2: 3-i4-methoxy-biphenyl-3~r1~ 1-methyl-12.5.6-tetrahs dr~o-pyridine The hydrochloride has a m.p. of 187-194°.
Example 3: 3-(2'-chloro-4-methoxy-biphenyl-3-yl)-1-meth 1-X1.2_,5,6-tetrahydro-p The by drogen oxalate has a m.p. of 137-142°.
Example 4: 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-propyl-1.2,5.6-tetrahydro-P
The compound is obtained as a yellow oil. TT,C (silica gel, toluene-EtOH-NH40H
85:15:1)Rf=0.25.
Examy,ple 5: 3-~(4-methoxy-4'-trifluoromethyl-biphenyl-3-~ -1-meth,~piperidine Palladium on charcoal ( 10%, 700 mg) is added to a degassed solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-1,2,5,6-tetrahydro-pyridine (obtained according to Example 1 ) (5.3 g, 15.9 mmol) in glacial acetic acid (75 ml) and the mixture hydrogenated on a Parr Hydrogenator for 18 hours at room temperature and 5 atm. hydrogen pressure, during which time 70 ml of hydrogen are taken up. The catalyst is then filtered off, and fresh catalyst added (0.800 g), and the mixture further hydrogenated for 18 hours at 45°
and 5 atm, hydrogen, after which time 400 ml of hydrogen are taken up. The suspension is then filtered, the solid washed with AcOH-~d the filtrates evaporated. The residue is treated with saturated aqueous K2C03 until a basic solution ensues, which is extracted with EtOAc. The organic extracts are washed with brine (30 mI), dried (MgS04) and evaporated to give the product as a light brown oil. The hydrogen maleinate has a m.p. of 93-96° (EtOH/Et~O, dec.).
The following compounds of formula I are prepared in analogous manner to Example 5.
Example 6: 3-(4-methoxy-biphenyl-3-yl)-1-methyl-piperidine The h~fdrochloride has a m.p. of 254-262°.
Example 7: 3-!2'-chloro-4-methox~-biphen~3-yl1-1-meth~rl-piperidine The by drochloride has a m.p. of 237-247°.
Example 8: 3-(4-methoxy-4'-trifluoromethgirl-biphenyl-3-vl)-1-prowl-pipericline The hydrogen fumarate of the racemate has a m.p. of 178-180°
(EtOH/Et20, dec.).
The racernate is resolved into its enantiomers by HPLC on Chiralcel OJ, column 25 x 0.46 cm, Mobile phase: Hexane-EtOH 9:1 with 0.1% TFA. Flow rate: 1mL/min. The first enantiomer elutes with retention time 8.35 min and the second with 10.25 min.
The enantiomers are crystallised as their corresponding fumarate salts, the first has (a)DZO
+24.4 (c = 1.0, MeOH), and the second (aJD2o _ _24.3 (c = 1.0, MeOH).
Examyle 9: (-)-3-(4-methoxy-4'-trifluoromethyl-biphenyl-3=y11-1-meth ~I-piperidine A solution of 3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-piperidine (obtained according to Example 5) (7.7 g, 22 rnmol) and (-)-2,3-di-o-toluyltartaric acid hydrate (8.9 g, 22 mmol) in warm (70°) EtOH (I00 ml) is allowed to cool to room temperature and left to stand for 18 hours. - the crystals so formed are filtered off and recrystallised from 100 ml EtOH, to give crystals with a rn.p. of 155-156°; [a)D2o - _77.8 (c = 1.0 MeOH). From the crystals thus obtained the free base is formed (oil;
[a)D2o - -9,3 (c = 0.95, MeOH). These crystals are recrystallised again from EtOH (80 ml), to give crystals with a mp of 159-160°, [a)D2o - _g3.0 (c = 1.0, MeOH); free base (oil): [a)D''° -12.5 (c = 0.9, MeOH}. The hydrogen maleate has a mp of 124-126°
(EtOHIEt20); [a)D2o - -6.2 (c = 1.0, MeOH).
Example 10: t+)-3-(4-methoxy-4'-triffuoromethvl-biphenyl-3-vll-1-meth l~l-piperidine The mother liquors from Example 9 are reserved, and free base is prepared from each by treating with sat. aqueous K2C03 and extraction with EtOAc. The free base obtained from the first mother liquors (2,4 g, 6.88 mmol) is treated with (+)-2,3-di-o-toluyltartaric acid hydrate (2.6 g, 6.88 mmol) in boiling EtOH (40 ml), which upon cooling yields crystals which are recrystallised from EtOH (25 ml) to give colourless crystals with a mp of 164-165°, [a)D2° _ + 81.1 (c = 1.1, MeOH) from which the free base has a [a)D2° of + 11.3 (c = 1.0, MeOH). The free base from the combined second and third mother liquors (3.6 g, 10.3 mmol) are combined with (+)-2,3-di-o-toluyitartaric acid hydrate (3.9 g, 10.3 mmol) in boiling EtOH (50 ml). After complete crystallisation , the crystals are recrystallised from EtOH (45 ml) to give a crop of crystals having a [a]n2° of +
85.2 (c = 1.0, MeOH) from which the free base has a [a)D2o of + 9.8 (c = 1.4, MeOH), and are further recrystallised from EtOH (30 ml) to give crystals with a m.p. of 164-165°;
[a)DZO = +87,3 (c = i.0, MeOH) from which the free base has a [a)D2o of + 11.3 (c = 1.0, MeOH). The hydrogen maleate has a m.p. of 125-127° (EtOH/Et20); [a)DZO
= + 5.4 (c =
1.1, MeOH) -Example 11: 3-(4-methoxy-4'-trifluorom~yl-biphenyl-3-vl~l-methyl-pyrrolidine A. 1-ethoxycarbonyl-3-(2-methoxyphenyl)-pyrrolidine A solution of ethylchloroformate (0.61 ml, 673 mg, 6.21 mmol) in CH2Cl2 (3 rnl) is added dropwise over 10 minutes to a cold (~5°, ice-bath) solution of N-ethyl-N,N-diisopropylamine (1.3 ml, 911 mg, 7.01 mmoi) and 3-(2-methoxyphenyi)-pyrrolidine (1.00 g, 5.65 mmol) in CH~C12 ( 15 rnl). The yellow reaction mixture is left to stir for 3.5 hours at room temperature, after which it is washed with 1N HCl ( 15 ml), saturated aqueous NaHC03 ( 15 ml) and brine ( 10 rnl), dried (MgS04) and the solvent evaporated to .give the product as a yellow oil. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf =
0.6.
B. 1-ethoxycarbonyl-3-(5-bromo-2-methoxyphenyl)-pyrrolidine A solution of bromine (835 mg, 5.22 matg) in glacial acetic acid (3 ml) is added dropwise to a solution of 1-ethoxycarbonyl-3-(2-methoxyphenyl)-pyrrolidine (1.300 g, 5.22 mmol) and sodium acetate (470 mg, 5.70 mmol) in glacial acetic acid (15 ml), and the mixture is left to stir for 18 hours at room temperature. The mixture is filtered through Hyflo and the solvent evaporated. The residue is taken up in ethyl acetate (30 ml) and the solution washed with water (20 ml), saturated aqueous Na2C03 (20 ml) and brine (15 rnl). The aqueous phases are extracted with EtOAc (25 ml) and the combined organic extracts dried (MgSOa) and evaporated to give the product as a yellow-brown oil [TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.6] which is used directly in the following reaction.
C. 1-ethoxycarbonyl-3-(4-methoxy-4'-tritluoromethlyl-biphenyl-3-yl)-pyrroliaine Obtained from 1-ethoxycarbonyl-3-(5-bromo-2-methoxyphenyl)-pyrrolidine and 4-trifluoromethylphenyl-boronic acid by palladium-catalysed coupling in analogous manner to Example 1B. TLC (silica gel, toluene-EtOH-NH40H 85:15:1) Rf = 0.78. The crude product is used directly in the following reaction.
D. 3-_(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-pyrrolidine The crude product obtained under C (2.00 g) is dissolved in THF (15 ml) and added dropwise over 15 minutes to a cold (0-5°) suspension of lithium aluminium hydride (350 mg, 9.2 mmol) in THF (25 ml). The reaction mixture is allowed to stir at room temperature for 1 hour and heated to reflux for 18 hours, after which it is allowed to cool to room temperature, and treated by t~ careful sequential addition of saturated aqueous NazSOa (2m1), 2N NaOH (2 ml), and Et20 (SO ml). The mixture is stirred vigorously 1 hour at room temperature, and the precipitate filtered off. The precipitate is further washed with Et20-THF (1:1 30 ml), and the combined filtrates dried (MgS04) and evaporated to give a reddish oil. This crude product is dissolved in Et20 (SO ml) and extracted with 2N HCl (2x 1S ml). The combined acid phases are further extracted with Et20 (20 ml), cooled (ice-bath), made alkaline with sat. aq.
K2C03 and extracted with Et20 (SO ml). The ether extracts are washed with brine (30 ml), dried (MgSOa) and evaporated to give the product as a reddish oil. TLC (silica gel, toluene-EtOH-NHaOH 8S:IS:1) Rf = 0.1. The hydrogen fumarate has a m.p. of I76-180°
(dec.).
Example 12 2 (4' trifluorometh~phenyl-3-vl)ethvlamine A mixture of 3-(bromophenyl)-ethylamine (1.400 g, 7.0 mmol) , 4-trifluoromethyl-phenylboronic acid (1.33 g, 7.0 mmol), tris-(ortho-toluyl)phosphine (212 mg, 0.70 mmol), palladium (II) acetate (160 mg, 0.7 rnmol), aqueous sodium carbonate solution (2M, 3.S ml), MeOH (2 ml) and toluene (2S ml) is heated to reflux under argon for 18 hours. The mixture is then allowed to cool to room temperature, and the phases are separated. The aqueous phase is extracted with toluene (2S ml). The combined organic phases are washed with water (2S rnl) and brine (30 ml), dried (MgS04) and evaporated. The residue is purified by chromatography (silica gel, toluene-ethanol-NH40H 85:15:1) to yield the product as a light yellow oil. TLC (silica gel, toluene-ethanol-NHaOH 8S:1S:1)Rf = 0.30.
Example I3 N N dimethvl 12 (4'-trifluoromethvl-biphenyl-3-vllethvllamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 150-153°
(EtOH/Et~O).
The compound can also be obtained by dimethylation of the compound of Example according to known procedures, e.g. by Eschwe~ler-Clarke methylation.
Example 14: 2-(6-methoxy-4'-tritluoromethLl-biphen~~yl)ethylamine Obtained analogously to Example 12 as a yellow oil. TLC (silica gel, toluene-EtOH-NH40H 85:15:1 ) Rf = 0.30.
Example 1S: N.N-dimethyl-f2-(6-methoxy-4'-trifluoromethyl-biphenyl-3-yl)ethyllarnine Obtained analogously to Example 12. The hydrochloride has a m.p, of 210-212°
(EtOH/Et20)..
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 14.
Example 16: 2-(4-methoxy-4'-tiifluoromethyl-biphenyl-3-yl)~thvlamine Obtained analogously to Example I2. The hydrogen rnaleate has a m.p. of 157-160°
(EtOH).
Example 17: N.N-dimeth~rl-2-f(4-methoxy-4'-trifluoromethyl-biphenyl-3-vl)ethyl-]amine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 136-137°
(EtOH).
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 16. -Example 18: N-propyl-2-[4-methoxy-4'-trifluorometh~phenyl-3-yl?Leth~lamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 178-180°
(EtOH/Et~O). -Example 19: 1-[2-f4-methoxv-4'-trifluommeth~phenyl-3-yllethyl]py~olidine Obtained analogously to example 12. The hydrogen maleate has a m.p. of 131-133°
(EtOHlEt20).
The compound can also be obtained as follows:
A. 1-[2-(4-methoxy-4'-tritluoromethyl-biphenyl-3-yl)-ethyl-pyrroIidine-2,5-dione A solution of 2-(4-methoxy-4'-trifluoromethylbiphenyl-3-yi)-ethylarnine (1.4 g, 4.74 mmol) and succinic anhydride (475 mg, 4.74 mmol) in THF (60 ml) is heated to reflux for I8 hours. The solution is then evaporated to dryness, and the residue heated to 190° to give an oil that crystallises on standing, and is recrystallised (Et20) to yield the product, m.p. 116-120°.
B. 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylJpyrrolidine A solution of 1-(2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyl-pyrrolidine-2,5-dione (1.3 g, 3.45 mmol) in THF (10 ml) is added dropwise over 10 minutes to a suspension of lithium aluminium hydride (262 mg, 6.9 mmol) in THF (15 ml) held at 0-10°. When the addition is complete, the mixture is allowed to warm up to room temperature, and stirred for 1 hour, after which the mixture is heated to reflux for i8 hours. After cooling, the reaction mixture is treated sequentially with saturated aqueous Na2SOa (2 ml) and aqueous NaOH (2N, 1 ml). After addition of Et20 (25 rnl) the resulting mixture is stirred for 1 hour, and then filtered. The precipitate is washed with Et20, and the washings combined with the filtrate. The Et20 solution is dried (MgS04) and evaporated to give a yellow oil which is purified by crystallisation as its hydrogen maleate.
Example 20: (1S''.2S~',6R"'.7R~)- 4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyll-10-oxa-4-aza-tricyclo [S .2.1.0 (,2 L6~] decane Obtained analogously to Example 12. The-hydrogen male ate has a rn.p. of 163-164°
(EtOH/Et20). The compound can also be obtained as follows:
A. (2S ;2R*,6S*',7R~')-4-[2-(4-methoxy- 4'-trifluoromethyl-biphenyl-3-yl)-ethyl]-10-oxa-4-aza-tricyclo[5.2.1.0(2,6)]decane-3,5-dione A solution of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)ethylamine (1.4 g, 4.74 mmol) and (IS*,2R *,6S*,7R *)-4,10-dioxa-tricyclo[5.2.1.0(2,6)]decane-3,5-dione (850 mg, 5.1 mmol) in THF (60m1) is heated to reflux for 18 hours, in similar fashion to example 8A, to give the product, mp. 166-168°.
B.(1S*',2S ;6R ;7R*')-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylJ-10-oxa-4-aza-tricyclo[5.2.1.0(2,6)]decane The product from Example 20A is reduced with lithium aiuminium hydride in THF
to give the product as a brown oil which is crystallised as its hydrogen maleate salt.
Example 21: f 1S'~.2S*.6R*.7R*1- 4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-eth~l~,-10-oxa-4-aza-2.6-dimeth I-~yclo[5.2.1.0(2.6)]decane Obtained analogously to Example 12. The hydrochloride has a m.p. of 229-231°. The compound can also be obtained as follows:
A. (IS~',2R ;6S*,7R*')-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyl]-10-oxa-4-aza-2,6-dimethyl-tricyclo [5 .2.1.0(2,6 ) J decane-3,5-dione Obtained in a similar fashion to example 20A from of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethylamine and (1 R *,2S*,6R *,7S*)-2,6-dimethyl-4,10-dioxa-tricyclo [5.2:1.0(2,6)]decane-3,S-dione. Mp. 115-117°
(Et20/hexane) B. (ZS*,2Sx,6R*',7R*)-4-[2~4-methoxy-4'-trifluorornethyl-biphenyl-3-yl)-ethyl]- I 0-oxa-4-aza-2,6-dimethyl-tricyclo [S .2.1.0 ( 2,6 ) ] decane Obtained in similar fashion to Example 20B by reduction of (I R *,2S *,6R *,7S
*)-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl~~:ethyl]-10-oxa-4-aza-2,6-dimethyl-tricyclo[5.2.1.0(2,6)]decane-3,5-dione.
Example 22 2-~,4'-isopropyl-4-methoxy-biphenyl-3-v11-ethvlamine Obtained analogously to Example 12. TLC (silica gel, EtOAc-MeOH-NH40H 0:20:2) Rf = 0.22.
Examvle 23~ N11T dimethYl_-2-(4'-isovropyl-4-methoxy-biphenyl-3-vl)-ethvlamine Obtained analogously to Example 12. The hydrogen maleate has a m.p. of 123-124°
(EtOH/Et~O).
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 22.
Examule 24- 2-(2'-chloro-4-methoxy-biphen~yll-ethvlamine Obtained analogously to Example 12. The hydrochloride has a m.p. of 191-205°.
ExamQ,le 25' N N-dimeth~l-2-!2'-chloro-4-methoxY biphenyl-3-vl)-ethvlamine Obtained analogously to Example 12. The hydrochloride has a m.p. of 151-159°.
The compound can also be obtained by Eschweiler-Clarke methylation of the compound of Example 24.
Exam,~le 26~ (2'-ehloro-4-methoxy-biphenyl-3-yl-methyl)-N,N-dimethvlamine Obtained analogously to Example 12. The hydrogen oxalate has a m.p. of 145-159°.
Example 27~ N.N dimethyl_-2-(2'-chloro-4-methoxy-biphen~-3-yl)-1-methyl-ethvlamine Obtained analogously to Example 12. The hydrochloride has a rn.p. of 141-145°.
Example 28~ (+) f2 f4 Methoxy-4'-trifluorometh~phenyl-3-ill-1-methyl-ethvll-N,N-dimethy_I-amine A. Z-1-Methoxy-2-(2-nitropropenyl)-benzene A solution of 10 g of 2-methoxybenzaldehyde, 6.07 g of nitroethane, 0.8 ml of butylamine and 30 ml of ethanol is refluxed for 3 days, the ethanol evaporated and the remaining mixture dissolved in ethyl acetate. After extraction with water and brine the solvent is evaporated and the residue bulb to bulb distilled. The fraction distilling at 120 - 170° I 0.01 mbar is purified on silicagel by elution with methylenechloride I
cyclohexane 1:1 giving the title compound in form of yellow plates, m.p. 39 -42°.
B. rac-2-(2-Methoxy-phenyl)-1-methyl-ethylamine A solution of 45.01 g (233 mmol) of Z-1-methoxy-2-(2-nitropropenyl)-benzene in ml of ether is slowly dropped into a flask equipped with a mechanical stirrer, thermometer and reflux condenser containing 40.84 g of LiAlH4 in 600 ml of diethyl ether. The exothermic reaction is cooled with ice and the temperature kept between 5 -10°. After stirring overnight at room temperature 330 ml of 2M Na2C03 are added, the resulting suspension filtered and the ether phase extracted with 2M HCI.
The acidic aqueous phase is made alkaline with 1.2 equivalents of conc. ammonia and extracted with diethyl ether. The ether phase is washed with brine, dried over Na2S04 and concentrated to afford the title compound as a yellow oil.'H-NMR (360 MHz, CDCl3):7.2t,1H;7.1d,1H;7.0-6.8m,2H;3.9s,3H;3.2m,1H;2.8m,1H;2.6 m, 1H; 1.1 d, 3H.
Further purification is achieved by transformation of the compound into the naphthalene-1,5-disulfonate salt.
C.1 (-)-2-(2-Methoxy-phenyl)-1-methyl-ethylamine To 19.16 g of rac-2-{2-methoxy-phenyl)-1-methyl-ethylamine dissolved in 300 ml of methanol a solution of 17.49 g of D-(-)-tarta~c acid in 334 ml of methanol is added and the mixture kept at 4° for 3 hours. The solid is filtered, the mother liquor put aside and the filter cake washed with ice-cold methanol and recristallised twice from methanol until the optical rotation remained constant. One obtains 11.11 g of (-)-2-(2-methoxy-phenyl)-1-methyl-ethylamine D-tartaric acid salt as fine white plates, m.p.
144 - 149°. The free base show a specific rotation of [a]ss9= -35.4° (c=1, MeOH).
Analytical chiral capillary electrophoresis of the free base reveals an optical purity of >98%.
C.2 (+)-2-(2-Methoxy-phenyl)-1-methyl-ethylamine The first mother liquor obtained in the preparation of the (-)-enantiomer of C.1 is concentrated and the residue liberated from the tartrate by treatment with conc.
ammonia and ethyl acetate. After evaporation of the organic layer, 11.14 g of a yellow oil are obtained and combined with 10.12 g of L-(+)-tartaric acid in a total volume of 140 ml of methanol. After 3 h at 4°, the formed solid is collected, washed with ice-cold methanol and recristallised from methanol until the specific rotation remains constant.
One obtains 11.92 g of (+)-2-(2-methoxy-phenyl)-1-methyl-ethylamine-L-tartaric acid salt as white plates. The free base show a specific rotation of [a]ss9 =
+37.7° (c=1, MeOH). Analytical chiral capillary electrophoresis reveals an optical purity of >98%.
D. (-)-[2-(2-Methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine 11.8 g of the tartaric acid salt of (+)-2-(2-methoxy-phenyl)-1-methyl-ethylamine are liberated with conc. ammonia in ethyl acetate and the obtained oil is dissolved in 56 ml of methanol. To this solution 22.3 ml of 36.5% aqueous formaldehyde solution are added, the mixture cooled to 3° and treated in small portions with 10.66 g of NaCNBH3. After 22 h of stirring at room temperature, the solvent is evaporated and the residue distributed between ethyl acetate and water. The organic phase is washed with water and brine, dried over Na2SC~, concentrated and the residue purified on silicagel by elution with toluene l ethyl acetate I methanol l conc. ammonia 60:30:10:1 yielding 5.02 g of the title compound as a yellow oil with [a]ss9 = -19.9° (c = 1, MeOH).'H-NMR (360 MHz, CDC13): 7.2 dxt, 1H; 7.1 dxd, 1H; 7.0 - 6.8 m, 2H;
3.85s,3H;3.1-3.Om,1H;2.95-2.85m,k~i;2.4brs,7H;0.95d,3H.
E. (+)-[2-(S-bromo-2-methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine To a mixture of 4.47 g of (-)-[2-(2-methoxy-phenyl)-1-methyl-ethyl]-dimethyl-amine, 2.09 g of sodium acetate and 40 ml of glacial acetic acid in a mechanically stirred flask, 1.19 mI of bromine in 8.5 ml of glacial acetic acid are added dropwise at 20 -30°. The reaction mixture is stirred for 16 h, neutralised with conc.
ammonia and extracted with ethyl acetate. Drying of the organic layer with brine and NazS04, evaporation of the solvent and purification of the obtained residue on silicagel with toluene I ethyl acetate I methanol I conc. ammonia 60:30:10:1 give 4.32 g of the title compound as a brown oil, [a)589 = +1.5° (c = 1.01, MeOH). 1H-NMR (360 MHz, CDC13):7.2-7.Om,2H;6.60d, 1H;3.70s,3H;2.95-2.75m,2H;2.3-2.2m+s, 7H; 0.85 d, 3H.
F. (+)-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-N,N-dimethyl-amine A 500 rnl-flask is charged with 140 ml of toluene and 28 ml of 2M Na2C03 and gased with argon for 1 h. Then 3.94 g of (+)-[2-(5-bromo-2-methoxy-phenyl)-1-methyl-ethyl]-dimethyl-amine, 4.95 g of 4-trifluoromethyl-phenylboronic acid and 374 mg of tetrakis(triphenylphosphine)palladium are added and the mixture is refluxed for 12 h.
The aqueous layer is extracted with ethyl acetate and the combined organic phases are washed with brine, dried over NazS04 and concentrated to afford a brown oil.
Formation of the naphthalene-1,5-disulfonate salt of this oil and liberation of the free base allow to cristallise the product as hydrochloride salt from HCl in diethyl ether.
Recristallisation ffom ethanol I ether afford the hydrochloride of the title compound as fine white plates, rn.p. 155 - 163°.
The free base solidifies with a m.p. of 36~- 37° and shows a specific rotation of [a]s89 =
+13.0° (c = 0.995, MeOH). Analytical chiral HPLC (Chiracel OJ) reveals an optical purity of >99%.'H-NMR (360 MHz, CDC13): 7.70 s, 4H; 7.45 dxd, 1H; 7.40 d, 1H;
6.95d,1H;3.90s,3H;3.25-3.20m,1H;3.0-2.9m,1H;2.55-2.45m,1H;2.40s, bH; 1.00 d, 1H.
Example 29: (-1-'[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl~-N.N-dirnethyl-amine A. (+)-[2-(2-methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared as described in example 28C.1 is reduced with NaCNBH3 and formaldehyde according to the description in example 28D to afford the title compound as a yellow oil, [a]ss9 = +21.6° (c = 1.03, MeOH).
B. (-)-[2-(5-bromo-2-methoxy phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared under A is brominated as described in example 28E to afford the title compound as a yellow oil, [a]ss9 = -1.0 (c = 1.05, MeOH).
C. (-)-[2-(4-methoxy-4'-triffuoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared under B is arylated with 4-trifluoromethyl-phenylboronic acid according to example 28F to afford the hydrochloride of the title compound as white plates, m.p. 148 - 163°.
The free base solidifies with a m.p. of 31° and shows a specific rotation of [a]ss9 =
-12.8° (c = 1.0, MeOH). Analytical chiral HPLC (Chiracel OJ) reveals an optical purity of >99%.
Example 30: ~1-(4-methoxy-4'-triffuorometh~phenyl-3-ylmethyll-propyll-N.N-dimethyl-amine A. 1-methoxy-2-(2-vitro-but-1-enyl)-benzene A solution of 2.72 g of 2-methoxybenzaIdehyde, 1.96 g of 1-nitropropane, 0.4 rnl of 1-butylamine and 10 ml of toluene is refluxed for 16 h. The toluene is evaporated and the residue dissolved in ethyl acetate and extracted with water and brine.
Concentration of the organic phase affords the title compound as yellow oil, sufficiently pure for the next step.'H-NMR (;,~60 MHz, CDCl3): 8.6 s (olefinic H of E-isorner); 8.2 s (olefinic H of Z-isomer).
B. 1-( 2-methoxybenzyl)-propylamine To a magnetically stirred mixture of 2.28 g of LiAIHa and 3S ml of diethyl ether a solution of 3.79 g of 1-methoxy-2-(2-nitro-but-1-enyl)-benzene in 1S ml of diethyl ether is dropped at 0 - S°. After stirring overnight at room temperature 20 ml of 2M
NazC03 are added, the resulting suspension is filtered and the organic phase extracted with 2M HCI. The acidic aqueous phase is made alkaline with 2M NaOH and extracted with methyl-t-butyl ether. The organic phase is washed with brine, dried over Na2S04 and concentrated to give the title compound as a yellow oil. 'H-NMR
(360 MHz,CDCl3):7.2-7.Om,2H;6.9-6.7m,2H;3.8s,3H;2.9m,1H;2.8dxd,lH;
2.4dxd,1H;l.Sm,lH;l.3m,1H;0.9t,3H.
C. 1-(S-bromo-2-methoxy-benzyl)-propylamine To a mixture of 2.25 g of 1-(2-methoxybenzyl)-propylamine, 1.13 g of sodium acetate and S7 ml of glacial acetic acid in a magnetically stirred flask, 0.65 ml of bromine in 3 ml of glacial acetic acid are added dropwise at 20 - 30°. The reaction mixture is stirred for 4 h, concentrated and the obtained residue distributed between water and ethyl acetate. The organic phase is extracted with 2M acetic acid and the combined acidic aqueous phases are made alkaline with conc. ammonia. Re-extraction with ethyl acetate, drying of the organic phase over Na2SOa and concentration give the title compound as colorless powder.'H-NMR (360 MHz, CDC13): 7.2 d, 1H; 7.1 s, 1H;
6.7 d, 1H; 3.8 s, 3H; 2.9 m, 1H; 2.7 m, 1H; 2.S m, 1H; 1.6 - 1.3 m, 2H; 1.0 t, 3H.
D. 1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl )-propyl]-amine A mixture of 1.91 g of 1-(S-bromo-2-methoxy-benzyl)-propylamine, 0.3 g of tetrakis(triphenylphosphine)palladium, 2.61 g of 4-trifluoromethyl-phenylboronic acid, 24 ml of 2M Na2C03 and 2S ml of toluene is refluxed under argon for 7 h.
After extraction of the water phase with diethyl ether, the organic phases are combined, dried over Na2S04 and concentrated to afford the title compound as a brown oil which is purified on silicagel by elution with toluepe I ethanol I conc. ammonia 8S:1S:1.'H-NMR (360 MHz, CDC13): 7.65 s, 4H; 7.S dxd, 1H; 7.4 d, 1H; 7.0 d, 1H; 3.9 s, 3H;
3.1m,1H;2.9dxd,1H;2.6dxd,1H;1.6m,1H;1.4m,1H,1.1t,3H.
E. [1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl)-propyl]-N,N-dimethyl-amine hydrochloride To a mixture of 1.25 g of 1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl)-propyl)-amine, 2.S ml of 36.5% formaline solution and 10 rnl of methanol under argon 1.66 g of NaCNBH3 are added in several portions at 3°. After stirring overnight at room temperature the solvent is evaporated and the residue distributed between ethyl acetate and water. The organic phase is washed with water and brine and concentrated to afford the crude product which is treated with HCl in diethyl ether.
The formed solid is filtered and recristallised from aceton / diethyl ether to give the title compound as white needles, m.p. 1SS - 172°.
Examine 31 1 f2 (4 methoxy 4' trifluoromethvl-biphenyl-3-~~)-1-methyl-eth ~ioeridine_ A. 2-(S-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine A mixture of 6.54 g of 2-(2-methoxy-phenyl)-1-methyl-ethylamine (free base, prepared as described in example 28B), 3.56 g of sodium acetate and 180 ml of glacial acetic acid is treated with 6.31 g of bromine as described in example 30C, affording the title compound as a yellow oil.'H-NMR (360 MHz, CDCl3): 7.4 - 7.2 m, 2H; 6.7 d, 1H;
3.8s,3H;3.2hex,1H;2.8-2.Sm,2H;1.1d,3H.
B. 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethylamine hydrochloride A mixture of 7.62 g of 2-(S-bromo-2-methoxy-phenyl)-1-methyl-ethylamine, 0.71 g of tetrakis(triphenylphosphine)palladium, Z.98 g of 4-trifluoromethyl-phenylboronic acid, 24 ml of 2M Na2C03, 40 ml of toluene and 10 ml of ethanol is refluxed for 9 h under argon. After workup similar to Example 30D, the crude oil is purified by transformation into the hydrochloride salt which is obtained in form of white plates.
'H-NMR (360 MHz, DMSO-d6): 7.90 - 7.7.~ dxd, 4H; 7.65 dxd, 1H; 7.60 d, 1H;
Example 29: (-1-'[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl~-N.N-dirnethyl-amine A. (+)-[2-(2-methoxy-phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared as described in example 28C.1 is reduced with NaCNBH3 and formaldehyde according to the description in example 28D to afford the title compound as a yellow oil, [a]ss9 = +21.6° (c = 1.03, MeOH).
B. (-)-[2-(5-bromo-2-methoxy phenyl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared under A is brominated as described in example 28E to afford the title compound as a yellow oil, [a]ss9 = -1.0 (c = 1.05, MeOH).
C. (-)-[2-(4-methoxy-4'-triffuoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-N,N-dimethyl-amine The product prepared under B is arylated with 4-trifluoromethyl-phenylboronic acid according to example 28F to afford the hydrochloride of the title compound as white plates, m.p. 148 - 163°.
The free base solidifies with a m.p. of 31° and shows a specific rotation of [a]ss9 =
-12.8° (c = 1.0, MeOH). Analytical chiral HPLC (Chiracel OJ) reveals an optical purity of >99%.
Example 30: ~1-(4-methoxy-4'-triffuorometh~phenyl-3-ylmethyll-propyll-N.N-dimethyl-amine A. 1-methoxy-2-(2-vitro-but-1-enyl)-benzene A solution of 2.72 g of 2-methoxybenzaIdehyde, 1.96 g of 1-nitropropane, 0.4 rnl of 1-butylamine and 10 ml of toluene is refluxed for 16 h. The toluene is evaporated and the residue dissolved in ethyl acetate and extracted with water and brine.
Concentration of the organic phase affords the title compound as yellow oil, sufficiently pure for the next step.'H-NMR (;,~60 MHz, CDCl3): 8.6 s (olefinic H of E-isorner); 8.2 s (olefinic H of Z-isomer).
B. 1-( 2-methoxybenzyl)-propylamine To a magnetically stirred mixture of 2.28 g of LiAIHa and 3S ml of diethyl ether a solution of 3.79 g of 1-methoxy-2-(2-nitro-but-1-enyl)-benzene in 1S ml of diethyl ether is dropped at 0 - S°. After stirring overnight at room temperature 20 ml of 2M
NazC03 are added, the resulting suspension is filtered and the organic phase extracted with 2M HCI. The acidic aqueous phase is made alkaline with 2M NaOH and extracted with methyl-t-butyl ether. The organic phase is washed with brine, dried over Na2S04 and concentrated to give the title compound as a yellow oil. 'H-NMR
(360 MHz,CDCl3):7.2-7.Om,2H;6.9-6.7m,2H;3.8s,3H;2.9m,1H;2.8dxd,lH;
2.4dxd,1H;l.Sm,lH;l.3m,1H;0.9t,3H.
C. 1-(S-bromo-2-methoxy-benzyl)-propylamine To a mixture of 2.25 g of 1-(2-methoxybenzyl)-propylamine, 1.13 g of sodium acetate and S7 ml of glacial acetic acid in a magnetically stirred flask, 0.65 ml of bromine in 3 ml of glacial acetic acid are added dropwise at 20 - 30°. The reaction mixture is stirred for 4 h, concentrated and the obtained residue distributed between water and ethyl acetate. The organic phase is extracted with 2M acetic acid and the combined acidic aqueous phases are made alkaline with conc. ammonia. Re-extraction with ethyl acetate, drying of the organic phase over Na2SOa and concentration give the title compound as colorless powder.'H-NMR (360 MHz, CDC13): 7.2 d, 1H; 7.1 s, 1H;
6.7 d, 1H; 3.8 s, 3H; 2.9 m, 1H; 2.7 m, 1H; 2.S m, 1H; 1.6 - 1.3 m, 2H; 1.0 t, 3H.
D. 1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl )-propyl]-amine A mixture of 1.91 g of 1-(S-bromo-2-methoxy-benzyl)-propylamine, 0.3 g of tetrakis(triphenylphosphine)palladium, 2.61 g of 4-trifluoromethyl-phenylboronic acid, 24 ml of 2M Na2C03 and 2S ml of toluene is refluxed under argon for 7 h.
After extraction of the water phase with diethyl ether, the organic phases are combined, dried over Na2S04 and concentrated to afford the title compound as a brown oil which is purified on silicagel by elution with toluepe I ethanol I conc. ammonia 8S:1S:1.'H-NMR (360 MHz, CDC13): 7.65 s, 4H; 7.S dxd, 1H; 7.4 d, 1H; 7.0 d, 1H; 3.9 s, 3H;
3.1m,1H;2.9dxd,1H;2.6dxd,1H;1.6m,1H;1.4m,1H,1.1t,3H.
E. [1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl)-propyl]-N,N-dimethyl-amine hydrochloride To a mixture of 1.25 g of 1-(4-methoxy-4'-trifluoromethyl-biphenyl-3-ylmethyl)-propyl)-amine, 2.S ml of 36.5% formaline solution and 10 rnl of methanol under argon 1.66 g of NaCNBH3 are added in several portions at 3°. After stirring overnight at room temperature the solvent is evaporated and the residue distributed between ethyl acetate and water. The organic phase is washed with water and brine and concentrated to afford the crude product which is treated with HCl in diethyl ether.
The formed solid is filtered and recristallised from aceton / diethyl ether to give the title compound as white needles, m.p. 1SS - 172°.
Examine 31 1 f2 (4 methoxy 4' trifluoromethvl-biphenyl-3-~~)-1-methyl-eth ~ioeridine_ A. 2-(S-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine A mixture of 6.54 g of 2-(2-methoxy-phenyl)-1-methyl-ethylamine (free base, prepared as described in example 28B), 3.56 g of sodium acetate and 180 ml of glacial acetic acid is treated with 6.31 g of bromine as described in example 30C, affording the title compound as a yellow oil.'H-NMR (360 MHz, CDCl3): 7.4 - 7.2 m, 2H; 6.7 d, 1H;
3.8s,3H;3.2hex,1H;2.8-2.Sm,2H;1.1d,3H.
B. 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethylamine hydrochloride A mixture of 7.62 g of 2-(S-bromo-2-methoxy-phenyl)-1-methyl-ethylamine, 0.71 g of tetrakis(triphenylphosphine)palladium, Z.98 g of 4-trifluoromethyl-phenylboronic acid, 24 ml of 2M Na2C03, 40 ml of toluene and 10 ml of ethanol is refluxed for 9 h under argon. After workup similar to Example 30D, the crude oil is purified by transformation into the hydrochloride salt which is obtained in form of white plates.
'H-NMR (360 MHz, DMSO-d6): 7.90 - 7.7.~ dxd, 4H; 7.65 dxd, 1H; 7.60 d, 1H;
7.15d,1H;3.85s,3H;3.Sm,1H;3.1-2.8rn,2H;1.15d,3H.
C. 4-[2-(4-methoxy-4'-triffuoromethyl-biphenyl-3-yl)-1-methyl-ethyl-carbamoyl]butyric acid The base of 1.1 g of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethylamine hydrochloride is liberated and reacted with 0.37 g of glutaric anhydride in THF under reflux for 20 h. The solvent is evaporated and the residue dissolved in ethyl acetate. After extraction of the organic phase with 1M HCI, water and brine, drying over Na~SOa and evaporation the title compound is obtained as a white powder, m.p.
88° (dec.).
D. 1-(2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine-2,6-dione A mixture of 1.02 g of the carboxylic acid obtained under C and 4.3 g of acetyl chloride in 20 ml of chloroform was refluxed for I7 h and, after cooling, extracted with water and 2M Na2C03. After drying of the organic phase over Na2SOa the solvent is evaporated and the residue purified on silicagel by elution with ethyl acetate I
cyclohexane 1:2, yielding the title compound as a bright yellow oil, solidifying in the refrigerator. 'H-NMR (360 MHz, CDCl3): 7.6 - 7.5 m, 4H; 7.4 dxd, 1H; 7.2 d, 1H;
6.8d,1H;5.2m,1H;3.8s,3H;3.2-3.Om,2H;2.4-2.3m,4H;1.5brm,ca.2H
(+HOD); 1.35 d, 3H.
E. 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine hydrochloride To a suspension of 0.054 g of LiAlH4 in 6 ml of diethyl ether under argon a solution of 0.3 g of 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine-2,6-dione in 2 ml of diethyl ether is drc.~gped under slight cooling. After stirring for 30 min 0.5 ml of 2M Na~COa are added, the resulting mixture is filtered and the filtrate acidified and extracted with 1M HCI. The aqueous phase is made alkaline with conc.
ammonia and extracted with diethyl ether. The organic phase, after drying over Na2S04, is concentrated and the residue treated with a solution of HCl in diethyl ether thereby affording the title compound as colorless plates, m.p.185°
(dec.).
Example 32~ N N-diethyl-j2-(4-methoxv-4'-trifluoromethyl-biphenyl-3-yl)-1-methvl-ethyl],=amine Obtained by reductive aIkylation of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-rnethyl-ethylamine (obtained as described in Example 31B) with acetaldehyde over 10% Pd/C in ethylacetate. The hydrochloride has a m.p. of 105-107°.
C. 4-[2-(4-methoxy-4'-triffuoromethyl-biphenyl-3-yl)-1-methyl-ethyl-carbamoyl]butyric acid The base of 1.1 g of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethylamine hydrochloride is liberated and reacted with 0.37 g of glutaric anhydride in THF under reflux for 20 h. The solvent is evaporated and the residue dissolved in ethyl acetate. After extraction of the organic phase with 1M HCI, water and brine, drying over Na~SOa and evaporation the title compound is obtained as a white powder, m.p.
88° (dec.).
D. 1-(2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine-2,6-dione A mixture of 1.02 g of the carboxylic acid obtained under C and 4.3 g of acetyl chloride in 20 ml of chloroform was refluxed for I7 h and, after cooling, extracted with water and 2M Na2C03. After drying of the organic phase over Na2SOa the solvent is evaporated and the residue purified on silicagel by elution with ethyl acetate I
cyclohexane 1:2, yielding the title compound as a bright yellow oil, solidifying in the refrigerator. 'H-NMR (360 MHz, CDCl3): 7.6 - 7.5 m, 4H; 7.4 dxd, 1H; 7.2 d, 1H;
6.8d,1H;5.2m,1H;3.8s,3H;3.2-3.Om,2H;2.4-2.3m,4H;1.5brm,ca.2H
(+HOD); 1.35 d, 3H.
E. 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine hydrochloride To a suspension of 0.054 g of LiAlH4 in 6 ml of diethyl ether under argon a solution of 0.3 g of 1-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-ethyl]-piperidine-2,6-dione in 2 ml of diethyl ether is drc.~gped under slight cooling. After stirring for 30 min 0.5 ml of 2M Na~COa are added, the resulting mixture is filtered and the filtrate acidified and extracted with 1M HCI. The aqueous phase is made alkaline with conc.
ammonia and extracted with diethyl ether. The organic phase, after drying over Na2S04, is concentrated and the residue treated with a solution of HCl in diethyl ether thereby affording the title compound as colorless plates, m.p.185°
(dec.).
Example 32~ N N-diethyl-j2-(4-methoxv-4'-trifluoromethyl-biphenyl-3-yl)-1-methvl-ethyl],=amine Obtained by reductive aIkylation of 2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-rnethyl-ethylamine (obtained as described in Example 31B) with acetaldehyde over 10% Pd/C in ethylacetate. The hydrochloride has a m.p. of 105-107°.
Claims (10)
1. A compound of formula I
wherein R1 and R2, independently, are hydrogen, (C1-4)alkyl, (C1-4)alkoxy, (C1-4)alkylthio, halogen, trifluoromethyl, trifluoromethoxy, cyano or (C2-5)alkanoyl, R3 is hydrogen, hydroxy, (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyloxy, halogen, cyano, (C2-5)alkanoyl, carbamoyl, (C1-4)alkylsalfonyloxy or trifluoromethyl-sulfonyloxy, R4 is hydrogen, hydroxy or (C1-4)alkoxy, and R5 is a group of formula (a), (b), (c) or (d) wherein R6 is (C1-4)alkyl, X is a straight or branched alkylene chain with 1 to 4 carbon atoms, and R7 and R8 form together with the nitrogen atom to which they are attached a group of formula (e) wherein Z is O, CH2 or CH2-CH2 and R9, R10, R11, R12, R3 and R14, independently,are H, halogen, (C1-4)alkyl or (C1-4)alkoxy, in free base or acid addition salt form.
wherein R1 and R2, independently, are hydrogen, (C1-4)alkyl, (C1-4)alkoxy, (C1-4)alkylthio, halogen, trifluoromethyl, trifluoromethoxy, cyano or (C2-5)alkanoyl, R3 is hydrogen, hydroxy, (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyloxy, halogen, cyano, (C2-5)alkanoyl, carbamoyl, (C1-4)alkylsalfonyloxy or trifluoromethyl-sulfonyloxy, R4 is hydrogen, hydroxy or (C1-4)alkoxy, and R5 is a group of formula (a), (b), (c) or (d) wherein R6 is (C1-4)alkyl, X is a straight or branched alkylene chain with 1 to 4 carbon atoms, and R7 and R8 form together with the nitrogen atom to which they are attached a group of formula (e) wherein Z is O, CH2 or CH2-CH2 and R9, R10, R11, R12, R3 and R14, independently,are H, halogen, (C1-4)alkyl or (C1-4)alkoxy, in free base or acid addition salt form.
2. A compound of formula I as defined in claim 1, wherein R1, R2, R3 and R4 are as defined in claim 1 and R5 is a group of formula (a), (b) or (c) as defined in claim 1, in free base or acid addition salt form.
3. A compound of formula I as defined in claim 1, wherein R1, R2, R3 and R4 are as defined in claim 1 and R5 is a group of formula (d) as defined in claim 1, in free base or acid addition salt form
4. A compound of claim 1 selected from (+)-3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-propyl-piperidine, (-)-3-(4-methoxy-4'-triouorornethyl-biphenyl-3-yl)-1-propyl-piperidine, (-)-3-(4-methoxy-4'-trifluorornethyl-biphenyl-3-yl)-1-methyl-piperidine, (+)-3-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-1-methyl-piperidine, (1S*,2S*,6R*,7R*)-4-[2-(4-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-ethyl]-10-oxa-4-aza-tricyclo [5.2.1.0(2,6)]decane, in free base or acid addition salt form.
5. A process for the production of a compound of formula I as defined in claim 1, in free base or acid addition salt form, whereby a compound of formula II, wherein R3, R4 and R5 are as defined in claim 1 and Y is halogen or trifluoromethylsulfonate, is reacted with a compound of formula III
wherein R1 and R2 are as defined in claim 1, and the resulting compound is recovered in free base form or in acid addition salt form.
wherein R1 and R2 are as defined in claim 1, and the resulting compound is recovered in free base form or in acid addition salt form.
6. A compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
7. A compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of epilepsy, stroke and brain or spinal trauma.
8. A pharmaceutical composition comprising a compound of anyone of claims 1 to in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
9. The use of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of epilepsy, stroke and brain or spinal trauma.
10. A method for the treatment of epilepsy, stroke and brain or spinal trauma, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9723134.4 | 1997-11-03 | ||
| GBGB9723134.4A GB9723134D0 (en) | 1997-11-03 | 1997-11-03 | Organic compounds |
| GBGB9723133.6A GB9723133D0 (en) | 1997-11-03 | 1997-11-03 | Organic compounds |
| GB9723133.6 | 1997-11-03 | ||
| PCT/EP1998/006880 WO1999023073A1 (en) | 1997-11-03 | 1998-10-30 | Biphenyl derivatives as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2308151A1 true CA2308151A1 (en) | 1999-05-14 |
Family
ID=26312535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002308151A Abandoned CA2308151A1 (en) | 1997-11-03 | 1998-10-30 | Biphenyl derivatives as pharmaceuticals |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1037876A1 (en) |
| JP (1) | JP2001521923A (en) |
| KR (1) | KR20010031699A (en) |
| CN (1) | CN1278249A (en) |
| AR (1) | AR016148A1 (en) |
| AU (1) | AU740448B2 (en) |
| BR (1) | BR9813897A (en) |
| CA (1) | CA2308151A1 (en) |
| CO (1) | CO5011067A1 (en) |
| ID (1) | ID24413A (en) |
| IL (1) | IL135580A0 (en) |
| NO (1) | NO20002321L (en) |
| NZ (1) | NZ503815A (en) |
| PE (1) | PE123599A1 (en) |
| PL (1) | PL339922A1 (en) |
| SK (1) | SK6412000A3 (en) |
| TR (1) | TR200001122T2 (en) |
| WO (1) | WO1999023073A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| TW200840566A (en) * | 2006-12-22 | 2008-10-16 | Esteve Labor Dr | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| US8642583B2 (en) | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
| WO2010059390A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Modulators of serotonin receptor |
| DE102009015697A1 (en) | 2009-03-31 | 2010-10-07 | Markus Dr. Heinrich | Process for the arylation of ring-substituted phenols and phenyl ethers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2114122A (en) * | 1938-04-12 | Alcohols and process fob making | ||
| DE674968C (en) * | 1935-01-15 | 1939-04-26 | Roehm & Haas Company | Process for the preparation of phenolic aralkylamino alcohols |
| US2040039A (en) * | 1935-02-26 | 1936-05-05 | Rohm & Haas | Phenolic morpholines |
| US2485550A (en) * | 1946-06-25 | 1949-10-25 | Hoffmann La Roche | Quaternary salts of carbamic acid esters of tertiary-hydroxybenzyl-amines |
| US2493710A (en) * | 1947-03-21 | 1950-01-03 | Hoffmann La Roche | Carbamic acid esters |
| US2872477A (en) * | 1957-04-05 | 1959-02-03 | Dow Chemical Co | alpha-(dialkylamino)-6-phenyl-o-cresol esters |
| JPS5328150A (en) * | 1976-08-25 | 1978-03-16 | Sugai Chemical Ind Co Ltd | Novel orthophenyl phenol derivative process for preparing same |
| EP0382213B1 (en) * | 1989-02-08 | 1995-05-10 | Otsuka Pharmaceutical Co., Ltd. | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent |
| US5428037A (en) * | 1993-04-09 | 1995-06-27 | Syntex Pharmaceuticals, Ltd. | Heterocyclic derivatives in the treatment of Ischaemia and related diseases |
| JPH072655A (en) * | 1993-06-18 | 1995-01-06 | Otsuka Pharmaceut Co Ltd | Agent for repairing or protecting denaturation of peripheral nerve |
| PT707007E (en) * | 1994-10-14 | 2002-06-28 | Merck Patent Gmbh | AMINO DERIVATIVES (TIO) ETER AS ACTIVE AGENTS IN THE CNS |
| EP0793662A1 (en) * | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Aminomethyl aryl compounds; dopamine receptor subtype selective ligands |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| DE19637237A1 (en) * | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazine derivatives |
-
1998
- 1998-10-29 CO CO98063635A patent/CO5011067A1/en unknown
- 1998-10-30 CN CN98810761A patent/CN1278249A/en active Pending
- 1998-10-30 EP EP98958884A patent/EP1037876A1/en not_active Withdrawn
- 1998-10-30 ID IDW20000790A patent/ID24413A/en unknown
- 1998-10-30 JP JP2000518948A patent/JP2001521923A/en active Pending
- 1998-10-30 AU AU14872/99A patent/AU740448B2/en not_active Ceased
- 1998-10-30 NZ NZ503815A patent/NZ503815A/en unknown
- 1998-10-30 TR TR2000/01122T patent/TR200001122T2/en unknown
- 1998-10-30 BR BR9813897-9A patent/BR9813897A/en not_active IP Right Cessation
- 1998-10-30 KR KR1020007004762A patent/KR20010031699A/en not_active Application Discontinuation
- 1998-10-30 WO PCT/EP1998/006880 patent/WO1999023073A1/en not_active Application Discontinuation
- 1998-10-30 CA CA002308151A patent/CA2308151A1/en not_active Abandoned
- 1998-10-30 PL PL98339922A patent/PL339922A1/en unknown
- 1998-10-30 SK SK641-2000A patent/SK6412000A3/en unknown
- 1998-10-30 IL IL13558098A patent/IL135580A0/en unknown
- 1998-10-30 AR ARP980105469A patent/AR016148A1/en not_active Application Discontinuation
- 1998-11-02 PE PE1998001034A patent/PE123599A1/en not_active Application Discontinuation
-
2000
- 2000-05-02 NO NO20002321A patent/NO20002321L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TR200001122T2 (en) | 2000-08-21 |
| KR20010031699A (en) | 2001-04-16 |
| BR9813897A (en) | 2000-09-26 |
| CN1278249A (en) | 2000-12-27 |
| NZ503815A (en) | 2002-05-31 |
| NO20002321D0 (en) | 2000-05-02 |
| PL339922A1 (en) | 2001-01-15 |
| ID24413A (en) | 2000-07-20 |
| JP2001521923A (en) | 2001-11-13 |
| IL135580A0 (en) | 2001-05-20 |
| WO1999023073A1 (en) | 1999-05-14 |
| CO5011067A1 (en) | 2001-02-28 |
| EP1037876A1 (en) | 2000-09-27 |
| AU1487299A (en) | 1999-05-24 |
| NO20002321L (en) | 2000-05-02 |
| AR016148A1 (en) | 2001-06-20 |
| AU740448B2 (en) | 2001-11-01 |
| PE123599A1 (en) | 1999-12-20 |
| SK6412000A3 (en) | 2000-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2606262C (en) | Novel histamine h3-receptor ligands and their therapeutic applications | |
| US6057371A (en) | Sigma receptor ligands and the use thereof | |
| RU2167146C2 (en) | Dimethyl-(3-arylbut-3-enyl)-amino-compounds and methods of their synthesis | |
| EP0591426A1 (en) | Sigma receptor ligands and the use thereof | |
| WO1995004028A1 (en) | Indane and tetrahydronaphthalene derivatives as calcium channel antagonists | |
| CZ210694A3 (en) | Derivatives of piperidine, their use for preparing pharmaceutical preparations, process of their preparation, intermediates for preparing thereof and pharmaceutical compositions based thereon | |
| CA2308151A1 (en) | Biphenyl derivatives as pharmaceuticals | |
| EP1978959B1 (en) | Piperidine and piperazine derivatives | |
| SK9812002A3 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives | |
| KR100435009B1 (en) | Tetralines Bearing a Phenyl Substituent on the Aromatic Ring and Their Use in the Treatment of Epilepsy, Stroke and Brain or Spinal Trauma | |
| DE60023898T2 (en) | ANTIPSYCHOTIC N-ARALKYL CYCLIC AMINE | |
| SK4952000A3 (en) | 3-amino-3-arylpropan-1-ol derivatives, process for their preparation, medicaments containing the same and their use | |
| CZ20001592A3 (en) | Novel derivatives of biphenyl, process of their preparation and pharmaceutical preparation containing thereof | |
| US8071602B2 (en) | Piperidine and piperazine derivatives | |
| EP0031910B1 (en) | Aniline derivatives, pharmaceutical preparations containing them and processes for their production | |
| US7342133B2 (en) | Substituted amino compounds as 5-HT/NA uptake inhibitors | |
| US20110281890A1 (en) | Piperidine and piperazine derivatives | |
| WO1998047889A1 (en) | Chroman derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |